UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended June 30, ~~2018.~~2019.

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from to .

Commission file number: 001-35347

Clovis Oncology, Inc.

(Exact name of Registrant as specified in its charter)


Delaware	90-0475355
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

5500 Flatiron Parkway, Suite 100
Boulder, Colorado	80301
(Address of principal executive offices)	(Zip Code)

~~(303)~~ (303) 625-5000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act


Title of Each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock par Value $0.001 per share	CLVS	The NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐◻

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes ☒⌧ No ☐◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒⌧		Accelerated filer	☐◻
Non-accelerated filer	☐◻	~~(Do not check if a smaller reporting company)~~	Smaller reporting company	☐
			Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of July ~~27, 2018~~26, 2019 was ~~52,649,591.~~54,656,539.

PART I. FINANCIAL INFORMATION

~~ITEM 1.FINANCIAL STATEMENTS~~
ITEM 1.
FINANCIAL STATEMENTS

CLOVIS ONCOLOGY, INC.

Consolidated Statements of Operations and Comprehensive Loss

~~CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS~~(Unaudited)

~~(Unaudited)~~

(In thousands, except per share amounts)

Three months ended June 30,

Six months ended June 30,


2018

2017

2018

2017

(in thousands, except per share amounts)
(in thousands, except per share amounts)
Revenues:




Product revenue

$
23,757

$
14,620

$
42,279

$
21,665
Operating expenses:








Cost of sales - product

4,490

2,730

8,495

3,893
Cost of sales - intangible asset amortization

709

372

1,080

743
Research and development

52,707

33,108

96,250

65,555
Selling, general and administrative

44,864

36,149

84,138

65,373
Total expenses

102,770

72,359

189,963

135,564
Operating loss

(79,013)

(57,739)

(147,684)

(113,899)
Other income (expense):








Interest expense

(3,581)

(2,598)

(6,216)

(5,178)
Foreign currency (loss) gain

(104)

76

(185)

(83)
Legal settlement loss

—

(117,000)

(7,975)

(117,000)
SEC settlement costs reserve

(20,000)

—

(20,000)

—
Other  income

1,475

594

2,883

946
Other expense, net

(22,210)

(118,928)

(31,493)

(121,315)
Loss before income taxes

(101,223)

(176,667)

(179,177)

(235,214)
Income tax benefit

33

1,281

292

1,365
Net loss

$
(101,190)

$
(175,386)

$
(178,885)

$
(233,849)
Other comprehensive income (loss):










Foreign currency translation adjustments, net of tax

(3,470)


2,812

(1,953)


3,279
Net unrealized gain (loss) on available-for-sale securities, net of tax

86


—

81


(5)
Other comprehensive (loss) income:

(3,384)


2,812

(1,872)


3,274
Comprehensive loss

$
(104,574)

$
(172,574)

$
(180,757)

$
(230,575)

Loss per basic and diluted common share:

Basic and diluted net loss per common share

$
(1.94)

$
(3.88)

$
(3.48)

$
(5.24)
Basic and diluted weighted average common shares outstanding

52,223

45,176

51,425

44,610


	Three months ended June 30,				Six months ended June 30,
	2019		2018		2019		2018
	(in thousands, except per share amounts)				(in thousands, except per share amounts)
Revenues:
Product revenue	$	32,978	$	23,757	$	66,096	$	42,279
Operating expenses:
Cost of sales - product		6,445		4,490		13,851		8,495
Cost of sales - intangible asset amortization		1,217		709		2,337		1,080
Research and development		70,746		52,707		132,777		96,250
Selling, general and administrative		48,029		44,864		95,791		84,138
Total expenses		126,437		102,770		244,756		189,963
Operating loss		(93,459)		(79,013)		(178,660)		(147,684)
Other income (expense):
Interest expense		(3,817)		(3,581)		(7,407)		(6,216)
Foreign currency loss		(226)		(104)		(419)		(185)
Legal settlement loss		(25,000)		(20,000)		(25,000)		(27,975)
Other income		1,899		1,475		4,300		2,883
Other expense, net		(27,144)		(22,210)		(28,526)		(31,493)
Loss before income taxes		(120,603)		(101,223)		(207,186)		(179,177)
Income tax benefit		176		33		336		292
Net loss	$	(120,427)	$	(101,190)	$	(206,850)	$	(178,885)
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax		(1)		(3,470)		(6)		(1,953)
Net unrealized gain on available-for-sale securities, net of tax		77		86		152		81
Other comprehensive (loss) income:		76		(3,384)		146		(1,872)
Comprehensive loss	$	(120,351)	$	(104,574)	$	(206,704)	$	(180,757)

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(2.27)	$	(1.94)	$	(3.91)	$	(3.48)
Basic and diluted weighted average common shares outstanding		53,028		52,223		52,960		51,425

See accompanying Notes to Unaudited Consolidated Financial Statements.

CLOVIS ONCOLOGY, INC.

Consolidated Balance Sheets

~~CONSOLIDATED BALANCE SHEETS~~(Unaudited)

~~(Unaudited)~~

(In thousands, except for share amounts)

June 30,

December 31,


2018

2017

ASSETS





Current assets:





Cash and cash equivalents

$
468,321

$
464,198

Accounts receivable, net

12,304

6,181

Inventories

62,989

27,508

Available-for-sale securities

213,921

99,533

Prepaid research and development expenses

2,723

1,559

Deposit on inventory

—

20,461

Other current assets

8,360

7,500

Total current assets

768,618

626,940

Deposit on inventory

53,937

—

Property and equipment, net

5,696

4,007

Intangible assets, net

53,480

19,561

Goodwill

63,475

65,217

Other assets

22,526

19,505

Total assets

$
967,732

$
735,230

LIABILITIES AND STOCKHOLDERS' EQUITY





Current liabilities:





Accounts payable

$
15,900

$
15,147

Accrued research and development expenses

19,788

18,465

Milestone liability

—

22,022

Accrued SEC settlement liability

20,000

—

Other accrued expenses

20,928

25,883

Total current liabilities

76,616

81,517

Convertible senior notes

574,335

282,406

Deferred rent, long-term

4,431

3,671

Total liabilities

655,382

367,594

Commitments and contingencies (Note 14)





Stockholders' equity:





Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2018 and December 31, 2017

—

—

Common stock, $0.001 par value per share, 100,000,000 shares authorized at June 30, 2018 and December 31, 2017; 52,637,375 and 50,565,119 shares issued and outstanding at June 30, 2018 and December 31, 2017 respectively

53

51

Additional paid-in capital

2,010,311

1,887,198

Accumulated other comprehensive loss

(44,045)

(42,173)

Accumulated deficit

(1,653,969)

(1,477,440)

Total stockholders' equity

312,350

367,636

Total liabilities and stockholders' equity

$
967,732

$
735,230


	June 30,		December 31,
	2019		2018

ASSETS
Current assets:
Cash and cash equivalents	$	108,607	$	221,876
Accounts receivable, net		15,375		12,889
Inventories, net		26,581		27,072
Available-for-sale securities		207,306		298,270
Prepaid research and development expenses		3,498		3,579
Other current assets		17,377		8,613
Total current assets		378,744		572,299
Inventories		107,670		113,908
Deposit on inventory		12,350		12,350
Property and equipment, net		15,802		26,524
Right-of-use assets, net		22,383		—
Intangible assets, net		65,343		51,930
Goodwill		63,074		63,074
Other assets		20,609		23,475
Total assets	$	685,975	$	863,560
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	18,503	$	28,517
Accrued research and development expenses		34,637		29,676
Lease liabilities		4,332		—
Accrued liability for legal settlement		21,000		—
Other accrued expenses		27,626		67,556
Total current liabilities		106,098		125,749
Long-term lease liabilities - less current portion		24,946		—
Convertible senior notes		576,763		575,470
Borrowings under financing agreement		6,893		—
Other long-term liabilities		1,257		15,872
Total liabilities		715,957		717,091
Commitments and contingencies (Note 15)
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2019 and December 31, 2018		—		—
Common stock, $0.001 par value per share, 200,000,000 and 100,000,000 shares authorized at June 30, 2019 and December 31, 2018, respectively; 53,170,479 and 52,797,516 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively		53		53
Additional paid-in capital		2,064,393		2,034,142
Accumulated other comprehensive loss		(44,488)		(44,634)
Accumulated deficit		(2,049,940)		(1,843,092)
Total stockholders' equity (deficit)		(29,982)		146,469
Total liabilities and stockholders' equity (deficit)	$	685,975	$	863,560

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

CLOVIS ONCOLOGY, INC.

Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited)


						Accumulated
				Additional		Other
	Common Stock			Paid-In		Comprehensive		Accumulated
	Shares	Amount		Capital		Income (Loss)		Deficit		Total
	(in thousands, except for share amounts)
January 1, 2019	52,797,516	$	53	$	2,034,142	$	(44,634)	$	(1,843,092)	$	146,469
Issuance of common stock under employee stock purchase plan	—		—		—		—		—		—
Exercise of stock options	83,132		—		1,093		—		—		1,093
Issuance of common stock from vesting of restricted stock units	113,402		—		—		—		—		—
Share-based compensation expense	—		—		13,639		—		—		13,639
Net unrealized gain on available-for-sale securities	—		—		—		75		—		75
Foreign currency translation adjustments	—		—		—		(5)		—		(5)
Net loss	—		—		—		—		(86,421)		(86,421)
March 31, 2019	52,994,050		53		2,048,874		(44,564)		(1,929,513)		74,850
Issuance of common stock under employee stock purchase plan	92,275		—		1,166		—		—		1,166
Exercise of stock options	20,741		—		223		—		—		223
Issuance of common stock from vesting of restricted stock units	63,413		—		—		—		—		—
Share-based compensation expense	—		—		14,130		—		—		14,130
Net unrealized gain on available-for-sale securities	—		—		—		77		—		77
Foreign currency translation adjustments	—		—		—		(1)		—		(1)
Net loss	—		—		—		—		(120,427)		(120,427)
June 30, 2019	53,170,479	$	53	$	2,064,393	$	(44,488)	$	(2,049,940)	$	(29,982)

CLOVIS ONCOLOGY, INC.

Table of Contents

Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited)


						Accumulated
				Additional		Other
	Common Stock			Paid-In		Comprehensive		Accumulated
	Shares	Amount		Capital		Income (Loss)		Deficit		Total
	(in thousands, except for share amounts)
January 1, 2018	50,565,119	$	51	$	1,887,197	$	(42,173)	$	(1,477,441)	$	367,634
Exercise of stock options	21,463		—		514		—		—		514
Issuance of common stock from vesting of restricted stock units	110,889		—		—		—		—		—
Share-based compensation expense	—		—		11,913		—		—		11,913
Net unrealized gain on available-for-sale securities	—		—		—		(5)		—		(5)
Foreign currency translation adjustments	—		—		—		1,517		—		1,517
Adoption of new revenue recognition standard	—		—		—		—		2,356		2,356
Net loss	—		—		—		—		(77,694)		(77,694)
March 31, 2018	50,697,471		51		1,899,624		(40,661)		(1,552,779)		306,235
Issuance of common stock, net or issuance costs	1,837,898		2		93,752		—		—		93,754
Issuance of common stock under employee stock purchase plan	35,636		—		1,377		—		—		1,377
Exercise of stock options	25,753		—		703		—		—		703
Issuance of common stock from vesting of restricted stock units	40,617		—		—		—		—		—
Share-based compensation expense	—		—		14,855		—		—		14,855
Net unrealized gain on available-for-sale securities	—		—		—		86		—		86
Foreign currency translation adjustments	—		—		—		(3,470)		—		(3,470)
Adoption of new revenue recognition standard	—		—		—		—		—		—
Net loss	—		—		—		—		(101,190)		(101,190)
June 30, 2018	52,637,375	$	53	$	2,010,311	$	(44,045)	$	(1,653,969)	$	312,350

Table of Contents

CLOVIS ONCOLOGY, INC.

CONSOLIDATED STATEMENTS OF CASH ~~FLOWS~~FLOWS

(Unaudited)

(In thousands)

Six months ended June 30,


2018

2017

Operating activities





Net loss

$
(178,885)

$
(233,849)

Adjustments to reconcile net loss to net cash used in operating activities:



Share-based compensation expense

26,768

19,563

Depreciation and amortization

1,507

1,281

Amortization of premiums and discounts on available-for-sale securities

693

245

Amortization of debt issuance costs

895

635

Legal settlement loss

—

117,000

Deferred income taxes

—

(1,266)

Changes in operating assets and liabilities:



Accounts receivable

(2,786)

(1,023)

Inventory

(35,543)

(6,478)

Prepaid and accrued research and development expenses

102

(15,162)

Deposit on inventory

(33,476)

—

Other operating assets

(3,881)

(36,855)

Accounts payable

860

3,202

Other accrued expenses

12,902

3,166

Net cash used in operating activities

(210,844)

(149,541)

Investing activities





Purchases of property and equipment

(2,208)

(249)

Deposits for purchases of property and equipment

—

(2,515)

Purchases of available-for-sale securities

(125,000)

(180,000)

Sales of available-for-sale securities

10,000

50,000

Acquired in-process research and development - milestone payment

(55,000)

(1,100)

Net cash used in investing activities

(172,208)

(133,864)

Financing activities





Proceeds from the sale of common stock, net of issuance costs

93,754

546,170

Proceeds from the issuance of convertible senior notes, net of issuance costs

291,035

—

Proceeds from the exercise of stock options and employee stock purchases

2,593

12,270

Net cash provided by financing activities

387,382

558,440

Effect of exchange rate changes on cash and cash equivalents

(207)

565

Increase (decrease) in cash and cash equivalents

4,123

275,600

Cash and cash equivalents at beginning of period

464,198

216,186

Cash and cash equivalents at end of period

$
468,321

$
491,786

Supplemental disclosure of cash flow information:





Cash paid for interest

$
3,594

$
3,594

Non-cash investing and financing activities:





Vesting of restricted stock units

$
8,357

$
2,627


	Six months ended June 30,
	2019		2018

Operating activities
Net loss	$	(206,850)	$	(178,885)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense		27,769		26,768
Depreciation and amortization		3,632		1,507
Amortization of premiums and discounts on available-for-sale securities		(884)		693
Amortization of debt issuance costs		1,324		895
Legal settlement loss		21,000		—
Allowance for obsolete inventories		289		—
Lease liabilities		(622)		—
Changes in operating assets and liabilities:
Accounts receivable		(2,491)		(2,786)
Inventory		(35,640)		(35,543)
Prepaid and accrued research and development expenses		5,041		102
Deposit on inventory		—		(33,476)
Other operating assets		(4,965)		(3,881)
Accounts payable		(1,393)		860
Other accrued expenses		(2,698)		12,902
Net cash used in operating activities		(196,488)		(210,844)
Investing activities
Purchases of property and equipment		(1,484)		(2,208)
Purchases of available-for-sale securities		(205,779)		(125,000)
Sales of available-for-sale securities		296,845		10,000
Acquired in-process research and development - milestone payment		(15,750)		(55,000)
Net cash provided by (used in) investing activities		73,832		(172,208)
Financing activities
Proceeds from the sale of common stock, net of issuance costs		—		93,754
Proceeds from the issuance of convertible senior notes, net of issuance costs		—		291,035
Proceeds from borrowings under financing agreement, net of issuance costs		6,862		—
Proceeds from the exercise of stock options and employee stock purchases		2,482		2,593
Net cash provided by financing activities		9,344		387,382
Effect of exchange rate changes on cash and cash equivalents		43		(207)
(Decrease) increase in cash and cash equivalents		(113,269)		4,123
Cash and cash equivalents at beginning of period		221,876		464,198
Cash and cash equivalents at end of period	$	108,607	$	468,321
Supplemental disclosure of cash flow information:
Cash paid for interest	$	5,469	$	3,594
Non-cash investing and financing activities:
Vesting of restricted stock units	$	4,283	$	8,357

See accompanying Notes to Unaudited Consolidated Financial Statements.

CLOVIS ONCOLOGY, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of Business and Basis of Presentation

Clovis Oncology, Inc. (together with its consolidated subsidiaries, the “Company”, “Clovis”, “we”, “our”, “us”) is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, ~~Europe~~the European Union (“EU”) and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. We have and intend to continue to license or acquire rights to oncology compounds in all stages of ~~clinical~~ development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in one segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities and since 2016 we have also marketed and sold products.

Our ~~marketed~~ product Rubraca® (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (“PARP”), is ~~approved~~marketed in the United States ~~by the Food and Drug Administration (“FDA”)~~ for two indications ~~encompassing two settings for the treatment of~~specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The initial ~~treatment~~ indication received approval from the United States Food and Drug Administration (“FDA”) in December 2016 and covers the treatment of adult patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. In April 2018, the FDA also approved Rubraca for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The ~~FDA granted regular~~ approval ~~for Rubraca~~ in this second, broader and earlier-line indication on a priority review timeline was based on positive data from the phase 3 ARIEL3 clinical trial. Diagnostic testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

In May 2018, the European Commission granted a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with ~~platinum sensitive,~~platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of ~~platinum based~~platinum-based chemotherapy, and who are unable to tolerate further ~~platinum based~~platinum-based chemotherapy. As this is a conditional approval, it will be necessary to complete certain confirmatory post marketing commitments, including ensuring that sufficient partially platinum sensitive patients are enrolled in our ARIEL4 confirmatory trial to support the indication. This may require enrollment of additional patients into the study, increasing its overall size and extending the time for enrollment.commitments. In ~~June 2018, we submitted to~~January 2019, the European ~~Union’s European Medicines Agency (“EMA”)~~Commission granted a variation to the marketing authorization ~~for~~to include the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based ~~chemotherapy,~~chemotherapy. With this approval, Rubraca is now authorized in the EU for ~~which we received EMA validation for this application~~certain patients in ~~July 2018. We anticipate an opinion on this application from~~ the ~~Committee for Medicinal Products for Human Use (“CHMP”) of the EMA by the end of 2018.~~

Beyond our initial labeled indication, we have a robust Rubraca clinical development program underway in a variety of solid tumor types, also including prostate and bladder cancers, and in July 2017, we entered into a broad clinical collaboration with Bristol-Myers Squibb Company to evaluate the combinationrecurrent ovarian cancer maintenance setting regardless of their ~~immunotherapy OPDIVO® (nivolumab)~~BRCA mutation status. Rubraca was the first PARP inhibitor licensed for an ovarian cancer treatment indication in the EU and is now the first to be authorized for both treatment and maintenance treatment among eligible patients with ovarian cancer. We completed our launch of Rubraca as maintenance therapy in ~~several tumor types. We hold worldwide rights for Rubraca.~~Germany and the United Kingdom in March 2019 and we plan to launch in other EU countries during 2019 and 2020.

In addition to Rubraca, we have ~~two~~one other product ~~candidates.~~

candidate. Lucitanib is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move the program forward. We have received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us later in 2018. We believe that recent data for a drug similar to lucitanib that

inhibits these same pathways – when combined with a PD-1 inhibitor – ~~provide support~~represent a scientific rationale for the development of lucitanib in combination with a ~~PD-(L)1~~PD-1 inhibitor, and ~~we intend to initiate~~ a Clovis-sponsored study of ~~the combination. We also intend to initiate~~lucitanib in combination with nivolumab is underway in advanced gynecologic cancers and other solid tumors. In addition, we have initiated a study of lucitanib in combination with Rubraca in ovarian cancer, based on encouraging data of VEGF and PARP inhibitors in combination. Each of these Phase 1b/2 studies is ~~expected to initiate in~~currently enrolling patients. We hold the ~~first quarter of 2019. We maintain certain development and commercialization rights for lucitanib. Following the termination of the Servier license agreement, we will have~~ global development and commercialization rights (except for China) for lucitanib.

Table of Contents

In early 2019, we provided notice to Celgene Corporation exercising the right to terminate our license to rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor (“EGFR”). ~~While we have stopped enrollment~~That termination became effective in ~~ongoing trials for rociletinib, we continue to provide drug to patients whose clinicians recommend continuing therapy. We have global development and commercialization rights for rociletinib.~~the second quarter of 2019.

Basis of Presentation

All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, ~~2017~~2018 (“~~2017~~2018 Form 10-K”) for a broader discussion of our business and the opportunities and risks inherent in such business.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

Liquidity

We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenues from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash.

In April 2018, we sold 1,837,898 shares of our common stock in a public offering at $54.41 per share. The net proceeds from the offering were $93.8 million, after deducting underwriting discounts and commissions and offering expenses. Concurrently, we completed the public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025. The net proceeds from this offering were $291.0 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and Europe, funding of our development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months.

~~Table of Contents~~

2. Summary of Significant Accounting Policies

Recently Adopted Accounting Standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, “Revenue from Contracts with Customers”, and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. Adoption of ASC 606 is required for annual and interim periods beginning after December 15, 2017. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We adopted the new standard using the modified retrospective method on January 1, 2018 for contracts that are not completed as of the adoption date.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. The standard also requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.

We examined our revenue recognition policy specific to revenue streams from contracts governing product sales from Rubraca and have come to conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. We reviewed all of our contracts, including our collaboration agreements with Servier and Bristol-Myers Squibb, and determined the potential impact to our accounting policies, financial controls and operations. Our conclusions include recognizing revenue on product sales once the product is sold to the specialty distributor and specialty pharmacy providers.

As noted above, we used the modified retrospective method to adopt the new standard. This means that we did not restate previously issued financial statements, but we recorded a one-time adjustment to retained earnings of $2.4 million. This adjustment represents the sales of our product to our customers prior to January 1, 2018, that had not been sold to patients or healthcare providers, offset by related gross-to-net adjustments and other direct costs, including royalties and sales incentive compensation.

~~The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASC 606 was as follows (in thousands):~~

Balance at

Adjustments due to

Balance at

December 31, 2017

Adoption of ASC 606

January 1, 2018
ASSETS

Accounts receivable, net

$
6,181

$
3,336

$
9,517
Inventories

$
27,508

(62)

$
27,446
    Total assets

$
735,230

$
3,274

$
738,504

LIABILITIES AND STOCKHOLDERS' EQUITY

Other accrued expenses

$
25,883

$
918

$
26,801
Accumulated deficit

$
(1,477,440)

2,356

$
(1,475,084)
    Total liabilities and stockholders' equity

$
735,230

$
3,274

$
738,504

Previously, we recognized revenue on product sales once the product was sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, i.e. when product is sold through the channel. Effective January 1, 2018, we began recognizing revenue when our customers, the specialty distributors and specialty pharmacy providers, take control of our product or when product is sold into the channel. This will have the impact of us recognizing revenue approximately two to four weeks earlier than before adopting the new standard and will also

~~Table of Contents~~

~~increase the significance of estimating variable consideration. The following financial statement line items for the three and six months ended June 30, 2018 were affected as a result of the adoption.~~

~~CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS~~

~~(In thousands, except for per share amounts)~~

Three months ended June 30, 2018




Balances without

Effect of Change

As reported

Adoption of ASC 606

Higher/(Lower)
Product revenue

$
23,757

$
20,372

$
3,385
Cost of sales - product

$
4,490

$
3,998

$
492
Selling, general and administrative

$
44,864

$
44,679

$
185
Net loss

$
(101,190)

$
(103,898)

$
(2,708)

Loss per basic and diluted common share:

Basic and diluted net loss per common share

$
(1.94)

$
(1.99)

$
(0.05)

Six months ended June 30, 2018




Balances without

Effect of Change

As reported

Adoption of ASC 606

Higher/(Lower)
Product revenue

$
42,279

$
38,328

$
3,951
Cost of sales - product

$
8,495

$
7,539

$
956
Selling, general and administrative

$
84,138

$
83,913

$
225
Net loss

$
(178,885)

$
(181,654)

$
(2,769)

Loss per basic and diluted common share:

Basic and diluted net loss per common share

$
(3.48)

$
(3.53)

$
(0.05)

~~CONSOLIDATED BALANCE SHEET~~

~~(In thousands)~~

June 30, 2018




Balances without

Effect of Change

As reported

Adoption of ASC 606

Higher/(Lower)
ASSETS

Accounts receivable, net

$
12,304

$
8,644

$
3,660
Inventories

$
62,989

$
62,887

$
102

LIABILITIES AND STOCKHOLDERS' EQUITY

Other accrued expenses

$
20,928

$
19,880

$
1,048
Accumulated deficit

$
(1,653,969)

$
(1,656,677)

$
(2,708)

ASC 606 did not have an aggregate impact on our net cash provided by operating activities but resulted in offsetting changes in certain assets and liabilities presented within net cash used in operating activities in our consolidated statement of cash flows, as reflected in the above tables.

~~Recently Issued Accounting Standards~~

From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification (“ASC”) are communicated through issuance of an ASU.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ~~Early~~

~~Table of Contents~~

~~adoption is permitted.~~ ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered after, the date of initial application, with an option to use certain transition relief. We adopted ASU 2016-02 as of January 1, 2019 using the modified retrospective method which leaves the comparative period reporting unchanged. Comparative reporting periods are ~~currently evaluating~~presented in accordance with Topic 840, while periods subsequent to the ~~impact~~effective date are presented in accordance with Topic 842. We have elected to adopt the package practical expedient which allows us: 1) to not reassess whether any expired or existing contracts are or contain leases, 2) to not reassess the lease classification for any expired or existing leases and 3) to not reassess initial direct costs for any existing leases. We also elected not to recognize on the balance sheet leases with terms of 12 months or less. For these short-term leases, we will recognize the lease payments in profit or loss on a straight-line basis over the lease term and the variable lease payments in the period in which the obligation for those payments is incurred.

Table of Contents

Adoption of the new lease standard ~~may have on our consolidated financial statements~~resulted in the recording of net right-of-use assets and ~~related disclosures.~~lease liabilities of approximately $24.9 million and $31.4 million, respectively, as of January 1, 2019.

In February 2018, the FASB issued ASU 2018-02, “Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”, which allow a reclassification from accumulated other comprehensive income (loss) (“AOCI”) to retained earnings for stranded tax effects resulting from the change in the U.S. federal corporate income tax rate on the gross deferred tax amounts at the date of enactment of the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We adopted the new standard on January 1, 2019 and elected not to reclassify the income tax effects of the Tax Act from AOCI to retained earnings. We continue to release disproportionate income tax effects from AOCI based on the aggregate portfolio approach. The adoption of this standard did not have an impact on our condensed consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”, simplifies the accounting for share-based payment granted to nonemployees for goods and services. Under the standard, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We adopted ASU 2018-07 as of January 1, 2019. There was no material impact on our consolidated financial statements and related disclosures.

Recently Issued Accounting Standards

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. We will adopt ASU 2018-02 as of January 1, 2020. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. We will adopt ASU 2016-13 as of January 1, 2020. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.

Revenue Recognition

We are currently approved to sell Rubraca in the United States ~~market.~~and the EU markets. We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently sell our products to patients and health care providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts.

Product Revenue

Revenue from product sales are recognized when the performance obligation is satisfied, which is when customers obtain control of our product at a point in time, typically upon delivery. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less.

Reserves for Variable Consideration

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from price concessions that include rebates,

Table of Contents

chargebacks, discounts, co-pay assistance, estimated product returns and other allowances that are offered within contracts between us and our customers, health care providers, payors and other indirect customers relating to the sales of our product. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customers) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known.

Rebates. Rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare coverage gap program. Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. The accrual for rebates is based on statutory discount rates and known sales to specialty pharmacy patients or expected utilization for specialty distributor sales to healthcare providers. As we gain more historical experience, the accrual will be based solely on the expected utilization from historical data we have accumulated since the Rubraca product launch. Rebates are generally invoiced and paid quarterly in arrears so that the accrual balance

~~Table of Contents~~

consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known or estimated prior quarters’ unpaid rebates.

Chargebacks. Chargebacks are discounts that occur when contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service organizations and federal government entities purchasing via the Federal Supply Schedule, purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the healthcare provider. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates and known sales to specialty distributors adjusted for the estimated utilization by healthcare providers.

Discounts and Fees. Our payment terms are generally 30 days. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized.

Co-pay assistance. Patients who have commercial insurance and meet certain eligibility requirements may receive co-pay assistance. The intent of this program is to reduce the patient’s out of pocket costs. Liabilities for co-pay assistance are based on actual program participation provided by third-party administrators at month end.

Returns. Consistent with industry practice, we generally offer customers a right of return limited only to product that will expire in six months or product that is six months beyond the expiration date. To date, we have had minimal product returns and we currently ~~do not~~ have ana minimal accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience.

Cost of Sales – Product

Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales.

Table of Contents

Cost of Sales – Intangible Asset Amortization

Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca.

Inventory

Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out (“FIFO”) basis. Inventories include active pharmaceutical ingredient (“API”), contract manufacturing costs and overhead allocations. We began capitalizing incurred inventory related costs upon the regulatory approval of Rubraca. Prior to the regulatory approval of Rubraca, we incurred costs for the manufacture of the drug that could potentially be available to support the commercial launch of Rubraca and all such costs were recognized as research and development expense.

We ~~periodically~~regularly analyze our inventory levels for excess quantities and obsolescence (expiration), taking into account factors such as historical and anticipated future sales compared to quantities on hand and the remaining shelf-life of Rubraca. Rubraca finished goods have a shelf-life of four years from the date of manufacture. The API currently has a shelf-life of four years from the date of manufacture but can be retested at an immaterial cost with no expected reduction in potency, thereby extending its shelf-life as needed. We expect to consume substantially all of the API over a period of approximately eight years based on our long-range sales projections of Rubraca.

We write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales ~~requirements as cost of product revenues.~~requirements. Expired inventory would be disposed of and the related costs would be written off as cost of product ~~revenues.~~ revenue. Inventories that are not expected to be consumed within 12 months following the balance sheet date are classified as long-term inventories. Long-term inventories primarily consist of API.

~~The active pharmaceutical ingredient (“API”) in Rubraca~~API is currently produced by a single supplier. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory. In addition, we currently manufacture Rubraca finished goods with a single third-party manufacturer. The disruption or termination of the supply of API or the disruption or termination of the manufacturing of our commercial products could have a material adverse effect on our business, financial position and results of operations.

Inventory used in clinical trials is expensed as research and development expense when it has been identified for such use.

Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies of the Notes to the Consolidated Financial Statements included in our ~~2017~~2018 Form 10-K.

~~Table of Contents~~

3. Financial Instruments and Fair Value Measurements

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The three levels of inputs that may be used to measure fair value include:

Level 1:	Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market ~~investments.~~investments and U.S. treasury securities. We do not have Level 1 liabilities.

Level 2:	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.

Table of Contents

Level 3:

Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets or liabilities that are measured at fair value on a recurring basis.

The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):


	Balance		Level 1		Level 2		Level 3
June 30, 2018

									Balance		Level 1		Level 2		Level 3
June 30, 2019
Assets:
Money market	$	422,029	$	422,029	$	—	$	—	$	67,093	$	67,093	$	—	$	—
U.S. treasury securities		213,921		—		213,921		—		207,306		—		207,306		—
Total assets at fair value	$	635,950	$	422,029	$	213,921	$	—	$	274,399	$	67,093	$	207,306	$	—
December 31, 2017
December 31, 2018
Assets:
Money market	$	433,136	$	433,136	$	—	$	—	$	81,968	$	81,968	$	—	$	—
U.S. treasury securities		99,533		—		99,533		—		308,251		9,981		298,270		—
Total assets at fair value	$	532,669	$	433,136	$	99,533	$	—	$	390,219	$	91,949	$	298,270	$	—

There we no liabilities that were measured at fair value on a recurring basis as of June 30, 2019. There were no transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the three and six months ended June 30, ~~2018.~~2019.

Financial instruments not recorded at fair value include our convertible senior notes. At June 30, ~~2018,~~2019, the carrying amount of the 2021 Notes was ~~$283.0~~$284.4 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was ~~$310.2~~$256.2 million. At June 30, ~~2018,~~2019, the carrying amount of the 2025 Notes was ~~$291.0~~$292.4 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was ~~$276.0~~$184.7 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of these notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 9, ~~Convertible Senior Notes~~10, Long-term Debt for discussion of the convertible senior notes.

4. Available-for-Sale Securities

As of June 30, 2019, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	207,189	$	117	$	—	$	207,306

As of December 31, 2018, available-for-sale securities consisted of the following (in thousands):

Gross

Gross

Aggregate

Amortized

Unrealized

Unrealized

Fair

Cost

Gains

Losses

Value

U.S. treasury securities

$
213,957

$
—

$
(36)

$
213,921


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	298,305	$	—	$	(35)	$	298,270

~~Table of Contents~~

~~As of December 31, 2017, available-for-sale securities consisted of the following (in thousands):~~

Gross

Gross

Aggregate

Amortized

Unrealized

Unrealized

Fair

Cost

Gains

Losses

Value

U.S. treasury securities

$
99,650

$
—

$
(117)

$
99,533

As of June 30, ~~2018, our~~2019, there were no available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months. We have concluded that decline in the market value of the available-for-sale securities is temporary. A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs.

As of June 30, ~~2018,~~2019, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):


	Amortized		Fair
	Cost		Value
Due in one year or less	$	207,189	$	207,306
Due in one year to two years		—		—
Total	$	207,189	$	207,306

Amortized

Fair

Cost

Value

Due in one year or less

$
213,957

$
213,921

Due in one year to two years

—

—

Total

$
213,957

$
213,921

Table of Contents

5. Inventories

The following table presents current and long-term inventories as of June 30, ~~2018~~2019 and December 31, ~~2017:~~2018:


	June 30,		December 31,
	2018		2017

					June 30,		December 31,
					2019		2018
Work-in-process	$	57,453	$	24,721	$	120,324	$	126,620
Finished goods		5,536		2,787		14,132		14,360
Allowance for obsolete inventories						(205)		—
Total inventories	$	62,989	$	27,508	$	134,251	$	140,980

Some of the costs related to our finished goods on-hand as of ~~June 30,~~December 31, 2018 were expensed as incurred prior to the commercialization of Rubraca on December 19, 2016.

At June 30, ~~2018,~~2019, we had $26.6 million of current inventory and $107.7 million of long-term inventory. In addition, we had $12.4 million long-term deposit on inventory, ~~on the Consolidated Balance Sheets is a cash deposit~~which consists of ~~$53.9 million made to a manufacturer for the purchase of work-in-process inventory~~API which we expect to be converted to finished goods and sold beyond the next twelve months.

6. Other Current Assets

Other current assets were comprised of the following (in thousands):


	June 30,		December 31,
	2018		2017

					June 30,		December 31,
					2019		2018
Prepaid insurance	$	1,403	$	1,926	$	1,054	$	243
Prepaid advertising						613		1,802
Prepaid legal						399		—
Prepaid IT						761		666
Prepaid expenses - other		4,768		3,355		3,178		2,672
Value-added tax ("VAT") receivable						9,634		—
Receivable - other		1,918		2,023		1,615		2,274
Other		271		196		123		956
Total	$	8,360	$	7,500	$	17,377	$	8,613

~~Table of Contents~~

7. Intangible Assets and Goodwill

Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):


	June 30,		December 31,
	2018		2017

					June 30,		December 31,
					2019		2018
Intangible asset - milestones	$	56,100	$	21,100	$	71,850	$	56,100
Accumulated amortization		(2,620)		(1,539)		(6,507)		(4,170)
Total intangible asset, net	$	53,480	$	19,561	$	65,343	$	51,930

The increase in our intangible asset – milestones since December 31, ~~2017~~2018 is due to a $15.0 million milestone payment to Pfizer related to the ~~April 6, 2018 FDA~~January 2019 European Commission approval and a $0.75 million milestone payment in June 2019 due to the launch of ~~our sNDA for~~ Rubraca as maintenance ~~treatment and a $20.0 million milestone payment to Pfizer related to the European Commission approval of Rubraca~~therapy in ~~May 2018.~~Germany in March 2019. See Note ~~12,~~ 13, License Agreements for further discussion of these approvals.

The estimated useful lives of these intangible assets are based on the estimated remaining patent life of Rubraca and extend through ~~2035.~~2031 in Europe and 2035 in the U.S.

We recorded amortization expense of $1.2 million and $2.3 million related to capitalized milestone payments during the three and six months ended June 30, 2019, respectively. We recorded amortization expense of $0.7 million and $1.1 million related to capitalized milestone payments during the three and six months ended June 30, ~~2018, respectively. We recorded amortization expense~~2018.

Table of ~~$0.4 million and $0.8 million related to capitalized milestone payments during the three and six months ended June 30, 2017, respectively.~~ Contents

Amortization expense is included in cost of sales – intangible asset amortization on the Consolidated Statements of Operations and Comprehensive Loss.

Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands):


2018	$	1,603

2019		3,209	$	2,423
2020		3,209		4,847
2021		3,209		4,847
2022		3,209		4,847
2023				4,847
Thereafter		39,041		43,532
	$	53,480
			$	65,343

~~The change in goodwill established as part of the purchase accounting of EOS in November 2013 consisted of the following (in thousands):~~

Balance at December 31, 2017

$
65,217

Change in foreign currency gains and losses

(1,742)

Balance at June 30, 2018

$
63,475

~~Table of Contents~~

8. Other Accrued Expenses

Other accrued expenses were comprised of the following (in thousands):


	June 30,		December 31,
	2018		2017

					June 30,		December 31,
					2019		2018
Accrued personnel costs	$	9,552	$	13,889	$	11,666	$	15,265
Accrued interest payable		2,846		2,096		2,921		2,721
Income tax payable		100		—		908		847
Accrued corporate legal fees and professional services		219		415		571		677
Accrued royalties		4,163		2,984		4,490		4,854
Accrued variable considerations		1,788		1,008		3,609		2,183
Payable to third party logistics provider		14		2,661
Current portion of capital lease obligations						—		1,031
Purchase of API received not yet invoiced						270		35,472
Accrued expenses - other		2,246		2,830		3,191		4,506
Total	$	20,928	$	25,883	$	27,626	$	67,556

9. ~~Convertible Senior Notes~~Lease

At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. We elected not to recognize on the balance sheet leases with terms of one year or less. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

The components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, maintenance, consumables, etc.) and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on fair values assigned to the lease components and non-lease components.

Our facilities operating leases have lease components, non-lease components and non-components, which we have separated because the non-lease components and non-components have variable lease payments and are excluded from the measurement of the lease liabilities. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis to the statements of operations.

We lease all of our office facilities in the U.S. and Europe. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.

Table of Contents

Most leases include one or more options to renew. The exercise of lease renewal options is at our sole discretion. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

We have a finance lease for certain equipment at the dedicated production train at Lonza, our non-exclusive manufacturer of the Rubraca API.

The components of lease expense and related cash flows were as follows (in thousands):


	Three months ended June 30,		Six months ended June 30,
	2019		2019
Lease cost
Finance lease cost:
Amortization of right-of-use assets	$	356	$	712
Interest on lease liabilities		179		363
Operating lease cost		994		2,144
Short-term lease cost		48		97
Variable lease cost		645		1,369
Total lease cost	$	2,222	$	4,685

Operating cash flows from finance leases	$	179	$	363
Operating cash flows from operating leases	$	994	$	2,144
Financing cash flows from finance leases	$	255	$	505

The weighted-average remaining lease term and weighted-average discount rate were as follows:


	June 30,
	2019
Weighted-average remaining lease term (years)
Operating leases		6.8
Finance leases		6.5
Weighted-average discount rate
Operating leases		8%
Finance leases		8%

Future minimum commitments due under these lease agreements as of June 30, 2019 are as follows (in thousands):


	Operating Leases		Finance Leases		Total
2019 (remaining six months)	$	2,410	$	868	$	3,278
2020		4,626		1,736		6,362
2021		4,737		1,736		6,473
2022		2,794		1,736		4,530
2023		2,350		1,736		4,086
Thereafter		9,874		3,472		13,346
Present value adjustment		(6,289)		(2,508)		(8,797)
Present value of lease payments	$	20,502	$	8,776	$	29,278

10. Long-term Debt

2021 Notes

On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “2021 Notes”) resulting in net proceeds of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

Table of Contents

The 2021 Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The 2021 Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year. The 2021 Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased.

Holders may convert all or any portion of the 2021 Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of 2021 Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the 2021 Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

On or after September 15, 2018, we may redeem the 2021 Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2021 Notes.

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the 2021 Notes, holders may require us to repurchase for cash all or any portion of the 2021 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2021 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The 2021 Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2021 Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

In connection with the issuance of the 2021 Notes, we incurred $9.2 million of debt issuance costs. The debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are

~~Table of Contents~~

amortized as interest expense over the expected life of the 2021 Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the 2021 Notes.

2025 Notes

On April 19, 2018, we completed an underwritten public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025 (the “2025 Notes”) resulting in net proceeds of ~~$291.0~~$290.9 million, after deducting underwriting discounts and commissions and offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

The 2025 Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the terms of that certain first supplemental indenture thereto. The 2025 Notes are senior unsecured obligations and bear interest at a rate of 1.25% per year, payable semi-annually in arrears on May 1 and November 1 of each year. The 2025 Notes will mature on May 1, 2025, unless earlier converted, redeemed or repurchased.

Holders may convert all or any portion of the 2025 Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 13.1278 shares per $1,000 in principal amount of 2025 Notes, equivalent to a conversion price of approximately $76.17 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the 2025 Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

Table of Contents

On or after May 2, 2022, we may redeem the 2025 Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the 2025 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2025 Notes.

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the 2025 Notes, holders may require us to repurchase for cash all or any portion of the 2025 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The 2025 Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2025 Notes; equal in right of payment to all of our liabilities that are not so subordinated, including the 2021 Notes; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

In connection with the issuance of the 2025 Notes, we incurred ~~$9.0~~$9.1 million of debt issuance costs. The debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the 2025 Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the 2025 Notes.

As of June 30, ~~2018~~2019 and December 31, ~~2017,~~2018, the balance of unamortized debt issuance costs related to the 2021 Notes and 2025 Notes was $10.7 million and $12.0 million, respectively.

TPG Financing Agreement

On May 1, 2019, we entered into a financing agreement with certain affiliates of TPG Sixth Street Partners, LLC (“TPG”) in which we plan to borrow from TPG amounts required to reimburse our actual costs and expenses incurred during each fiscal quarter (limited to agreed budgeted amounts), as such expenses are incurred, related to the ATHENA clinical trial, in an aggregate amount of up to $175 million. ATHENA is our largest clinical trial, with a planned target enrollment of 1,000 patients across more than 270 sites in at least 25 countries. The Clovis-sponsored phase 3 ATHENA study in advanced ovarian cancer is the first-line maintenance treatment setting evaluating Rubraca plus nivolumab (PD-1 inhibitor), Rubraca, nivolumab and a placebo in newly-diagnosed patients who have completed platinum-based chemotherapy. This study initiated in the second quarter of 2018 and is currently enrolling patients.

We expect to incur borrowings under the financing agreement on a quarterly basis, beginning with an initial draw of $8.6 million upon the execution of the financing agreement with respect to such expenses incurred during the quarter ended March 31, 2019 and ending generally on the earliest to occur of (i) the termination of the ATHENA Trial, (ii) the date of completion of all activities under the ATHENA Trial Clinical Study Protocol, (iii) the date on which we pay the Discharge Amount (as defined in the financing agreement), (iv) the date of the occurrence of a change of control of us (or a sale of all or substantially all of our assets related to Rubraca) or our receipt of notice of certain breaches by us of our obligations under material in-license agreements related to Rubraca and (v) September 30, 2022.

We are obligated to repay the loan on a quarterly basis, beginning on the earliest to occur of (i) the termination of the ATHENA Trial, (ii) the approval by the FDA of an update to the label portion of the Rubraca new drug application (“NDA”) to include in such label the treatment of an indication resulting from the ATHENA Trial, (iii) the date on which we determine that the results of the ATHENA Trial are insufficient to achieve such an expansion of the Rubraca label to cover an indication based on the ATHENA Trial and (iv) September 30, 2022.

Payments are based on a certain percentage of the revenues generated from the sales and any future out-licensing of Rubraca with quarterly payment capped at $8.5 million, unless the label portion of the Rubraca NDA is expanded by the FDA to include such label the treatment of an indication resulting from the ATHENA Trial, in which case the quarterly payment is capped at $13.5 million. The maximum amount required to be repaid under the agreement is two times the aggregate borrowed amount, which may be $350 million in the event we borrow the full $175 million under the financing agreement.

Table of Contents

In the event we have not made payments on or before December 30, 2025 equal to at least the borrowed amount, we are required to make a lump sum payment in an amount equal to such borrowed amount less the aggregate of all prior quarterly payments described above. All other payments are contingent on the performance of Rubraca. There is no final maturity date on the financing agreement.

Our obligations under the financing agreement will be secured under a Pledge and Security agreement by a first priority security interest in all of our assets related to Rubraca, including intellectual property rights and a pledge of the equity of our wholly owned subsidiaries, Clovis Oncology UK Limited and Clovis Oncology Ireland Limited. In addition, the obligations will initially be guaranteed by Clovis Oncology UK Limited and Clovis Oncology Ireland Limited, secured by a first priority security interest in all the assets of those subsidiary.

For the six months ended June 30, 2019, we recorded the $8.6 million initial draw as a long-term liability on the Consolidated Balance Sheet and future quarterly draws will be recorded as a long-term liability on the Consolidated Balance Sheet. As of June 30, 2019, we incurred $1.7 million of debt issuance costs. The debt issuance costs are presented as a deduction from the TPG financing liability on the Consolidated Balance Sheet and are amortized as interest expense over the expected life of the financing agreement using the straight-line method. As of June 30, 2019, the balance of unamortized debt issuance costs was ~~$13.2 million~~$1.7 million.

For the six months ended June 30, 2019,we used an effective interest rate of 14.8%. For subsequent periods, we will use the prospective method whereby a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and ~~$5.1 million, respectively~~.it will be used to recognize interest expense for the remaining periods. Under this method, the effective interest rate is not constant, and any change in expected cash flows is recognized prospectively as an adjustment to the effective yield.

~~Table of Contents~~

The following table sets forth total interest expense recognized during the three and six months ended June 30, ~~2018~~2019 and ~~2017~~2018 (in thousands):


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
Contractual interest expense	$	2,547	$	1,797	$	4,344	$	3,594

									Three months ended June 30,				Six months ended June 30,
									2019		2018		2019		2018
Interest on 2021 Notes and 2025 Notes									$	2,734	$	2,547	$	5,469	$	4,344
Amortization of debt issuance costs										679		569		1,324		895
Interest on finance lease										179		—		363		—
Interest on borrowings under financing agreement										199		—		199		—
Accretion of interest on milestone liability		465		483		977		949		—		465		—		977
Amortization of debt issuance costs		569		318		895		635
Other interest										26		—		52		—
Total interest expense	$	3,581	$	2,598	$	6,216	$	5,178	$	3,817	$	3,581	$	7,407	$	6,216

~~10.~~11. Stockholders’ Equity

Common Stock

The holders of common stock are entitled to one vote per share on all matters to be voted upon by our stockholders. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors.

Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities.

Table of Contents

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended June 30, ~~2018~~2019 and ~~2017,~~2018, as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2018		2017		2018		2017		2018		2017

													Foreign Currency				Unrealized				Total Accumulated
													Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
													2019		2018		2019		2018		2019		2018
Balance at April 1,	$	(40,400)	$	(46,967)	$	(261)	$	(151)	$	(40,661)	$	(47,118)	$	(44,465)	$	(40,400)	$	(99)	$	(261)	$	(44,564)	$	(40,661)
Other comprehensive income (loss)		(3,944)		4,451		88		(3)		(3,856)		4,448
Other comprehensive (loss) income														(1)		(3,944)		77		88		76		(3,856)
Total before tax		(44,344)		(42,516)		(173)		(154)		(44,517)		(42,670)		(44,466)		(44,344)		(22)		(173)		(44,488)		(44,517)
Tax effect		474		(1,639)		(2)		3		472		(1,636)		—		474		—		(2)		—		472
Balance at June 30,	$	(43,870)	$	(44,155)	$	(175)	$	(151)	$	(44,045)	$	(44,306)	$	(44,466)	$	(43,870)	$	(22)	$	(175)	$	(44,488)	$	(44,045)

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the six months ended June 30, ~~2018~~2019 and ~~2017,~~2018, as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2018		2017		2018		2017		2018		2017

													Foreign Currency				Unrealized				Total Accumulated
													Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
													2019		2018		2019		2018		2019		2018
Balance at January 1,	$	(41,917)	$	(47,434)	$	(256)	$	(146)	$	(42,173)	$	(47,580)	$	(44,460)	$	(41,917)	$	(174)	$	(256)	$	(44,634)	$	(42,173)
Other comprehensive income (loss)		(1,953)		5,186		81		(8)		(1,872)		5,178
Other comprehensive (loss) income														(6)		(1,953)		152		81		146		(1,872)
Total before tax		(43,870)		(42,248)		(175)		(154)		(44,045)		(42,402)		(44,466)		(43,870)		(22)		(175)		(44,488)		(44,045)
Tax effect		—		(1,907)		—		3		—		(1,904)		—		—		—		—		—		—
Balance at June 30,	$	(43,870)	$	(44,155)	$	(175)	$	(151)	$	(44,045)	$	(44,306)	$	(44,466)	$	(43,870)	$	(22)	$	(175)	$	(44,488)	$	(44,045)

The period change in each of the periods was primarily due to the ~~currency translation of the goodwill and~~ deferred income taxes associated with the acquisition of EOS in November 2013. There were no reclassifications out of accumulated other comprehensive loss in each of the three and six months ended June 30, ~~2018~~2019 and ~~2017.~~2018.

~~Table of Contents~~

~~11.~~12. Share-Based Compensation

Share-based compensation expense for all ~~equity based~~equity-based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and six months ended June ~~30,~~31, 2019 and 2018 ~~and 2017~~ was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows (in thousands):


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017

									Three months ended June 30,				Six months ended June 30,
									2019		2018		2019		2018
Research and development	$	4,966	$	4,825	$	10,342	$	8,991	$	6,633	$	4,966	$	13,244	$	10,342
Selling, general and administrative		9,889		5,792		16,426		10,572		7,497		9,889		14,525		16,426
Total share-based compensation expense	$	14,855	$	10,617	$	26,768	$	19,563	$	14,130	$	14,855	$	27,769	$	26,768

We did not recognize a tax benefit related to share-based compensation expense during the three and six months ended June 30, ~~2018~~2019 and ~~2017, respectively,~~2018, as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of June 30, ~~2018.~~2019.

Table of Contents

Stock Options

The following table summarizes the activity relating to our options to purchase common stock for the six months ended June 30, ~~2018:~~2019:

Weighted


Weighted

Average

Aggregate

Average

Remaining

Intrinsic

Number of

Exercise

Contractual

Value

Options

Price

Term (Years)

(Thousands)

Outstanding at December 31, 2017

5,789,735

$
46.77





Granted

475,768

56.47





Exercised

(47,091)

25.82





Forfeited

(114,991)

62.86





Outstanding at June 30, 2018

6,103,421

$
47.39

6.8

$
68,594

Vested and expected to vest at June 30, 2018

5,864,188

$
47.21

6.7

$
67,088

Vested and exercisable at June 30, 2018

4,129,536

$
45.35

5.9

$
54,282


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value
	Options	Price		Term (Years)	(Thousands)
Outstanding at December 31, 2018	6,311,513	$	46.05
Granted	861,887		21.71
Exercised	(103,873)		12.67
Forfeited	(251,924)		55.19
Outstanding at June 30, 2019	6,817,603	$	43.15	6.2	$	3,116
Unvested as of June 30, 2019	6,556,485	$	43.51	6.1	$	3,103
Vested and exercisable at June 30, 2019	4,696,283	$	46.62	5.0	$	3,016

The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of ~~$45.47~~$14.87 as of June ~~29, 2018,~~28, 2019, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.

The following table summarizes information about our stock options as of and for the three and six months ended June 30, ~~2018~~2019 and ~~2017~~2018 (in thousands, except per share amounts):


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017

									Three months ended June 30,				Six months ended June 30,
									2019		2018		2019		2018
Weighted-average grant date fair value per share	$	35.56	$	44.94	$	41.69	$	46.53	$	11.33	$	35.56	$	15.81	$	41.69
Intrinsic value of options exercised	$	610	$	4,759	$	1,372	$	14,284	$	198	$	610	$	963	$	1,372
Cash received from stock option exercises	$	702	$	5,439	$	1,216	$	11,113	$	222	$	702	$	1,316	$	1,216

As of June 30, ~~2018,~~2019, the unrecognized share-based compensation expense related to unvested options, adjusted for expected forfeitures, was ~~$66.2~~$50.0 million and the estimated weighted-average remaining vesting period was ~~2.52~~2.2 years.

~~Table of Contents~~

Restricted Stock

The following table summarizes the activity relating to our unvested restricted stock units (“RSUs”) for the six months ended June 30, ~~2018:~~2019:

Weighted

Average

Number of

Grant Date

Units

Fair Value

Unvested at December 31, 2017

589,529

$
41.67

Granted

406,440

57.22

Vested

(151,599)

39.55

Forfeited

(33,365)

45.29

Unvested as of June 30, 2018

811,005

$
49.71

Expected to vest after June 30, 2018

689,899

$
49.36



		Weighted
		Average
	Number of	Grant Date
	Units	Fair Value
Unvested at December 31, 2018	795,684	$	47.73
Granted	2,029,274		25.52
Vested	(176,815)		50.24
Forfeited	(161,626)		35.42
Unvested as of June 30, 2019	2,486,517	$	30.22
Expected to vest after June 30, 2019	2,100,892	$	30.41

As of June 30, ~~2018,~~2019, the unrecognized share-based compensation expense related to unvested RSUs, adjusted for expected forfeitures, was ~~$31.5~~$58.5 million and the estimated weighted-average remaining vesting period was ~~3.17~~2.5 years.

~~12.~~21

Table of Contents

13. License Agreements

Rucaparib

In June 2011, we entered into a worldwide license agreement with Pfizer, Inc. to obtain exclusive global rights to develop and commercialize ~~rucaparib, a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), used for the treatment of selected solid tumors.~~Rubraca. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of ~~rucaparib, discussed below,~~Rubraca, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense.

On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1^st Indication in US and (ii) EMA approval of an MAA for 1^st Indication in EU, to a date that is 18 months after the date of achievement of such milestones.

On December 19, 2016, ~~the~~Rubraca received its initial FDA ~~approved Rubraca~~(rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. The FDAapproval. This approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was ~~made~~paid in the first quarter of 2017. ~~The~~This FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. We paid the $23.0 million milestone payment in June 2018.

On April 6, 2018, ~~the~~Rubraca received a second FDA approved our sNDA for Rubraca as maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.approval. This approval resulted in ~~the~~an obligation to pay a $15.0 million milestone payment, which we paid in April 2018.

In May 2018, ~~the~~Rubraca received its initial European Commission granted a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.approval. This approval resulted in ~~the~~an obligation to pay a $20.0 million milestone payment, which we paid in June 2018.

In January 2019, Rubraca received its second European Commission approval. This approval resulted in an obligation to pay a $15.0 million milestone payment, which we paid in February 2019.

In June 2019, we paid a $0.75 million milestone payment due to the launch of Rubraca as maintenance therapy in Germany in March 2019.

These milestone payments were recognized as intangible assets and will be amortized over the estimated remaining useful life of Rubraca.

~~Table of Contents~~

We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize ~~rucaparib~~Rubraca and we are responsible for all remaining development and commercialization costs for ~~rucaparib.~~Rubraca. We are required to make regulatory milestone payments to Pfizer of up to an additional ~~$31.75~~$16.0 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for ~~rucaparib~~Rubraca are met, which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize ~~rucaparib.~~Rubraca.

The license agreement with Pfizer will remain in effect until the expiration of all of our royalty and sublicense revenue obligations to Pfizer, determined on a product-by-product and country-by-country basis, unless we elect to terminate the license agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Pfizer can terminate the agreement, resulting in a loss of our rights to Rubraca and an obligation to assign or license to Pfizer any intellectual property rights or other rights we may have in Rubraca, including our regulatory filings, regulatory approvals, patents and trademarks for Rubraca.

In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with ~~rucaparib~~Rubraca under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of ~~rucaparib~~Rubraca for the uses claimed by these patents. AstraZeneca receives royalties on any net sales of ~~rucaparib.~~Rubraca.

Table of Contents

Lucitanib

~~Lucitanib~~

In connection with our acquisition of EOS in November 2013, we gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for upfront milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments.

In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, after giving effect to the first and second amendments to the license agreement, we are required to pay to Advenchen 25% of any consideration, excluding royalties, ~~received pursuant to any sublicense agreements for lucitanib, including~~we receive from sublicensees, in lieu of the ~~agreement with Servier.~~milestone obligations set forth in the agreement. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product candidate containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib.

The license agreement with Advenchen will remain in effect until the expiration of all our royalty obligations to Advenchen, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Advenchen can terminate the agreement, resulting in a loss of our rights to lucitanib.

During 2017, we completed the committed on-going development activities related to lucitanib and received full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of ~~Operations.~~Operations and Comprehensive Loss. Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move the program forward. We ~~have~~ received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us ~~later in~~during October 2018.

Pursuant to terms of each of our product license agreements, we will pay royalties to our licensors on sales, if any, of the respective products.

Rociletinib

~~We are party to a product~~In May 2010, we entered into an exclusive worldwide license agreement ~~for~~with Celgene to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor (“EGFR”) gene product. Rociletinib, an oral mutant-selective inhibitor of EGFR, was identified as the lead inhibitor candidate under the license agreement. Following the termination of enrollment in all sponsored clinical studies of rociletinib, we provided notice of termination to Celgene of our ~~other drug candidate~~license rights to rociletinib, ~~(see our 2017 Form 10-K for additional details).~~an oral mutant-selective inhibitor of EGFR, and that termination became effective in the second quarter of 2019.

~~13.~~14. Net Loss Per Common Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the 2021 Notes and 2025 Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):


	Three and Six months ended June 30,
	2018	2017
Common shares under option	3,723	6,373

			Three and Six months ended June 30,
			2019	2018
Common shares under option plans			3,133	3,723
Convertible senior notes	8,584	4,646	8,584	8,584
Total potential dilutive shares	12,307	11,019	11,717	12,307

~~14.~~

15. Commitments and Contingencies

Royalty and License Fee Commitments

We have entered into certain license agreements, as identified in Note ~~12,~~ 13, License Agreements, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. Our payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, we only recognize payment obligations which are probable and estimable as of the balance sheet date. Milestone liabilities of $0.0 million and $22.0 million are recorded on our Consolidated Balance Sheets at June 30, 2018 and December 31, 2017, respectively, and relate to milestone payments for the licensing of our rucaparib product, which was approved by the FDA on December 19, 2016.

Manufacture and Services Agreement Commitments

On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for Rubraca. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in Rubraca that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified in any forecast. In addition, the third-party supplier will construct, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the Rubraca active ingredient. We are obligated to make scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Further, once the ~~facility is~~production train became operational in October 2018, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of June 30, ~~2018, $147.8~~2019, $101.3 million of purchase commitments exist under the Agreement.

At the time we entered into the Agreement, we evaluated the Agreement as a whole and bifurcated into lease and non-lease components, which consisted of an operating lease of warehouse space, capital lease of equipment, purchase of leasehold improvements and manufacturing costs based upon the relative fair values of each of the deliverables. During October 2018, the production train was placed into service and we recorded the various components of the Agreement.

Legal Proceedings

We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition.

Rociletinib-Related Litigation

Following Clovis’ regulatory announcement in November 2015 of adverse developments in its ongoing clinical trials for rociletinib, Clovis and certain of its current and former executives were named in various securities lawsuits, the largest of which was a putative class action lawsuit in the District of Colorado (the “Medina Action”) which was settled on October 26, 2017 (the “Medina Settlement”). The ~~open~~remaining actions ~~currently pending against Clovis~~ are discussed below.

Table of Contents

efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the

~~Table of Contents~~

Antipodean Complaint also ~~asserts~~asserted Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint ~~seeks~~sought compensatory, recessionary, and punitive damages.

On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the ~~“Antipodean Amended~~“Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint.

On ~~January 31, 2017,~~June 14, 2019, Clovis and Antipodean entered into an agreement (the “Settlement Agreement”) to settle the ~~defendants filed a motion~~lawsuit. Pursuant to ~~stay~~ the Settlement Agreement, Clovis agreed to pay Antipodean ~~action pending resolution~~$4.0 million in cash and issue 1,482,058 shares of common stock of the ~~Medina Action in the District of Colorado. On March 14, 2017, the Clovis defendants~~Company (the “Settlement Shares”) and Antipodean ~~participated in a mediation, which did not result in a settlement.~~

~~On March 29, 2017, the defendants filed a motion~~agreed to dismiss the Antipodean Amended Complaint. On August 8, 2017, Justice Masley of the New York Supreme Court, County of New York granted the defendants’ motion to stay. Per the Court’s August 10, 2017 order, the defendants’ motion to dismiss was held in abeyancelawsuit and deemed submitted on November 1, 2017. On November 1, 2017, the defendants provided a status update to the Court regarding the outcome of the hearing. The update informed the Court that Antipodean had excluded itself from the Medina Settlement, as memorialized in the final judgment entered by the Medina Court.

On April 17, 2018, the parties participated in a Preliminary Conference, following which the Court entered a preliminary conference order, providing for, among other things, an end date for discovery of February 4, 2019.

~~On May 2, 2018, the Court issued an order denying the defendants’ motion to dismiss. Defendants filed an answer to the Antipodean Amended Complaint on June 6, 2018.~~

~~The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint. However, there can be no assurance that the defense will be successful.~~

In March 2017, two putative shareholders of the Company, Macalinao and McKenry (the “Derivative Plaintiffs”), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In rerelease Clovis, ~~Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”).~~

On May 18, 2017, the Derivative Plaintiffs filed a Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint purported to rely on documents produced by the Company in response to prior demands for inspection of the Company’s books and records served on the Company by each of Macalinao and McKenry under 8 Del. C. § 220. The Consolidated Derivative Complaint sought, among other things, an award of money damages.

On July 31, 2017, the defendants filed a motion to dismiss the Consolidated Derivative Complaint. Plaintiffs filed an opposition to the motion to dismiss on August 31, 2017, and the defendants filed a reply in further support of the motion to dismiss on September 26, 2017. Oral argument on the defendants’ motion to dismiss the Consolidated Derivative Complaint has been scheduled for February 4, 2019.

~~The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful.~~

~~On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the “Guo Complaint”) against certain~~its officers and directors ofand underwriters from any potential liability related to the ~~Company~~allegations asserted in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company’s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the

~~Table of Contents~~

Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages.

~~On June 19, 2017, the parties filed a joint motion to stay the Guo action pending resolution of the motion to dismiss the Consolidated Derivative~~Amended Complaint. ~~On June 20, 2017, the court granted the motion to stay.~~

~~The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful.~~

As previously disclosed, the Company has received inquiries and requests for information from governmental agencies, including the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice, relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. On April 9, 2018, the Company received a “Wells Notice” letter from the staff of the SEC issued in connection with this investigation. In addition, the Company’s CEO, Patrick Mahaffy, also received a Wells notice. These Wells Notices advised that the staff had made a preliminary determination to recommend to the SEC that it file an action against the Company and Mr. Mahaffy regarding possible violations of the federal securities laws. The Company and Mr. Mahaffy then submitted Wells Submissions explaining their view that no enforcement action was warranted to the SEC staff.

Following these submissions, the Company and Mr. Mahaffy then engaged in discussions with the SEC staff to resolve this matter. The Company has now reached an agreement in principle with the SEC staff to settle this matter on negligence-based charges. Pursuant to the proposed settlement, without admitting or denying the SEC’s allegations, the Company would agree to pay a $20.0 million civil penalty, which the Company reserved as a loss contingency on its consolidated balance sheet as of June 30, 2018, and would stipulate to a standard injunction against future violations of those provisions of the federal securities laws. Mr. Mahaffy has separately reached an agreement in principle with the SEC staff on similar negligence-based allegations, to which he would neither admit nor deny, and pay a civil penalty and be similarly enjoined. Mr. Mahaffy will continue to serve as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors.

The proposed settlements would not allege that the Company or any of its current or former officers engaged in any intentional fraud or misconduct. The proposed settlements are subject to approval by the SEC and will also require approval by the United States District Court where the settlements are ultimately filed. There can be no assurances that the proposed settlements ultimately will be approved on these terms by either the SEC or the court, or when the settlements will be finalized. Once finalized, the settlements will resolve the SEC’s nearly three year investigation into the regulatory approval process of rociletinib.

~~Director Compensation Litigation~~

On May 10, 2017, John Solak, a purported shareholder of the Company, filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware (the “Solak Complaint”) against certain directors and an officer of the Company. The Solak Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by adopting a compensation plan that overcompensated the non-employee director defendants, in relation to companies of comparable market capitalization and size. The Solak Complaint also alleged claims of waste of corporate assets and unjust enrichment. The Solak Complaint sought, among other things, an award of money damages and the imposition of corporate governance reforms.

On February 26, 2018, the defendants entered into a stipulation of compromise and settlement with plaintiff that was intended to settle the Solak action. On May 30, 2018, the Court approved the stipulation upon the conclusion of a settlement hearing concerning the fairness of the terms of the proposed settlement. In accordance with the terms of the settlement, as incorporated by reference in the Court’s Order and Final Judgment entered on the day of the hearing, the Company presented a new non-employee director compensation policy for shareholder vote at its 2018 annual shareholder meeting. Pursuant to the settlement, the Company is also instituting a number of corporate governance reforms, including, enhanced proxy disclosures, the codification of the Company’s stock ownership guidelines for directors, and enhanced disclosure requirements for certain forms of director compensation. While no cash payments

~~Table of Contents~~

~~were made to investors as part of the settlement, the court awarded a plaintiff’s fee of $395,000, which the Company paid on June 4, 2018.~~ The settlement ~~contained~~contains no admission of wrongdoing.

~~European Patent Opposition~~

~~Two oppositions were filed in the granted European counterpart~~The cash portion of the ~~rucaparib camsylate salt/polymorph patent~~settlement was paid on June 20, 2017. The grounds of opposition related to Rubraca were lack of novelty and lack of inventive step. A preliminary opinion and summons to oral proceedings were issued on April 4, 2018. The oral hearing is scheduled for December 4, 2018. The preliminary opinion provides a non-binding indication of the tribunal’s view. In the preliminary opinion, the tribunal agree with some of our positions and agree with certain objections made by the opponents. As part of the proceeding, we have the opportunity to submit further argument and pursue alternative claims in the form of auxiliary requests. While the ultimate results of patent challenges can be difficult to predict, we believe a number of factors, including a constellation of unexpected properties, support the novelty and non-obviousness of our rucaparib camsylate salt/polymorph composition of matter patent.

~~ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS~~

~~Forward-Looking Information~~

This Quarterly Report on Form 10-Q and the information incorporated herein by reference includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned non-clinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein.

Any forward-looking statements that we make in this Quarterly Report on Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

You should also read carefully the factors described in the “Risk Factors” in Part I, Item 1A in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”), as updated from time to time in our subsequent SEC filings, to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements.

~~Overview~~

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.

~~Table of Contents~~

Our marketed product Rubraca® (rucaparib) is approved in the United States by the Food and Drug Administration (“FDA”) for two indications, encompassing two settings for the treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The initial treatment indication received in December 2016 covers the treatment of adult patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. In April 2018, the FDA also approved Rubraca for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Diagnostic testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

In May 2018, the European Commission granted a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. As this is a conditional approval, it will be necessary to complete confirmatory post marketing commitments, including ensuring that sufficient partially platinum sensitive patients are enrolled in our ARIEL4 confirmatory trial to support the indication. This may require enrollment of additional patients into the study, increasing its overall size and extending the time for enrollment. In June 2018, we submitted to the EMA a variation to the marketing authorization for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, for which we received EMA validation for this application in July 2018. We anticipate an opinion on this application from the CHMP of the EMA by the end of 2018.

In June 2011, we obtained an exclusive, worldwide license from Pfizer to develop and commercialize rucaparib. U.S. Patent 6,495,541, and its equivalent counterparts issued in dozens of countries, directed to the rucaparib composition of matter, expire in 2020 and are potentially eligible for up to five years patent term extension in various jurisdictions. We believe that patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the “Hatch-Waxman Act”) could be available to extend our patent exclusivity for rucaparib to the fourth quarter of 2023 in the United States. In Europe, we believe that patent term extension under a supplementary protection certificate could be available for an additional five years for one European patent directed to Rubraca. In April 2012, we obtained an exclusive license from AstraZeneca under a family of patents and patent applications which will permit the development and commercialization of rucaparib for certain methods of treating patients with PARP inhibitors. Additionally, other patents and patent applications are directed to methods of making, methods of using, dosing regimens, various salt and polymorphic forms and formulations and have expiration dates ranging from 2020 through potentially 2035, including the camsylate salt/polymorph patent family licensed from Pfizer, which expires in 2031 and a patent family directed to high dosage strength rucaparib tablets that expires in 2035. As of May 3, 2018, the rucaparib camsylate salt/polymorph patent was issued in 47 countries to date (including US and Europe), with applications pending in 9 countries, and the rucaparib composition of matter patent was issued in 48 countries. We are aware of a number of challenges of salt and polymorph patents. Two oppositions were filed in the granted European counterpart of the rucaparib camsylate salt/polymorph patent on June 20, 2017. European oppositions are commonly filed against patents related to pharmaceutical products. The grounds of opposition related to Rubraca were lack of novelty and lack of inventive step. The novelty and inventive step challenges are based on prior art references (or closely related disclosures) that were previously raised by the European patent examiner during prosecution of the application. The claims of the granted patent were found to be patentable over this prior art. A preliminary opinion and summons to oral proceedings were issued on April 4, 2018. The oral hearing is scheduled for December 4, 2018. The preliminary opinion provides a non-binding indication of the tribunal’s view. In the preliminary opinion, the tribunal agree with some of our positions and agree with certain objections made by the opponents. As part of the proceeding, we have the opportunity to ~~submit further argument andpursue alternative claims in the form of auxiliary requests.~~ While the ultimate results of patent challenges can be difficult to predict, we believe a number of factors, including a constellation of unexpected properties, support the novelty and non-obviousness of our rucaparib camsylate salt/polymorph composition of matter

~~Table of Contents~~

patent. We believe a successful challenge of all claims relevant to Rubraca would be difficult. Our high dosage strength rucaparib tablets patent issued in the United States on June 5, 2018, with claims that cover the commercial Rubraca product, including all commercial dosage strengths expires in 2035. Additionally, in Europe, regulatory exclusivity is available for ten years, plus one year for a new indication, therefore, we have regulatory exclusivity for Rubraca in Europe until 2028, and if an additional indication is approved, until 2029.

~~In addition to Rubraca, we have two other product candidates.~~

Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move the program forward. We have received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us later in 2018. We believe that recent data for a drug similar to lucitanib that inhibits these same pathways – when combined with a PD-1 inhibitor – provide support for development of lucitanib in combination with a PD-(L)1 inhibitor, and we intend to initiate a study of the combination. We also intend to initiate a study of lucitanib in combination with Rubraca, based on encouraging data of VEGF and PARP inhibitors in combination. Each of these studies is expected to initiate in the first quarter of18, 2019. We maintain certain development and commercialization rights for lucitanib. Following the termination of the Servier license agreement, we will have global development and commercialization rights (except for China) for lucitanib.

Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (“EGFR”). While we have stopped enrollment in ongoing trials for rociletinib, we continue to provide drug to patients whose clinicians recommend continuing therapy. We have global development and commercialization rights for rociletinib.

We commenced operations in April 2009. To date, we have devoted substantially all of our resources to identifying and in-licensing product candidates, performing development activities with respect to those product candidates and the general and administrative support of these operations. ThroughAt June 30, ~~2018, we have generated $13.6 million in license and milestone revenue related to our collaboration and license agreement with Servier and~~2019, the liability for the six months ended June 30, 2018 and 2017 have generated $42.3 million and $21.7 million, respectively, product revenue related to sales of Rubraca, which we began to commercialize on December 19, 2016. We have principally funded our operations using the net proceeds from the sale of convertible preferred stock, the issuance of ~~convertible promissory notes, public offerings~~the shares was recorded to accrued liability for legal settlement on the Consolidated Balance Sheets in the amount of ~~our~~$21.0 million. Clovis issued the Settlement Shares on July 1, 2019, whereby the issuance of the shares was recorded in common stock and additional paid-in capital and the accrued liability for legal settlement was cleared.

Clovis registered under the Securities Act the resale of the Settlement Shares by Antipodean. On July 3, 2019, pursuant to the Settlement Agreement, Clovis and Antipodean filed a Stipulation of Discontinuance with Prejudice, which was entered by the court on July 5, 2019.

As the Settlement Agreement is in response to the alleged violation of securities laws by certain of our ~~convertible senior notes offering.~~

Weofficers, we have ~~never been profitable~~determined that the resulting loss does not relate to activities that are in the normal course of our operations and as of June 30, 2018, we had an accumulated deficit of $1,654.0 million. We incurred net losses of $178.9 million and $233.8 million for the six months ended June 30, 2018 and 2017, respectively. We had cash, cash equivalents and available-for-sale securities totaling $682.2 million at June 30, 2018.

~~We expect to incur significant~~therefore, should not be recognized in operating losses for the ~~foreseeable future, as~~period. Accordingly, we ~~incur costs related to commercial activities~~have recognized the entire expense associated ~~with Rubraca.~~ In April 2018, we sold 1,837,898 shares of our common stock in a public offering at $54.41 per share. The net proceeds from the offering were $93.8 million, after deducting underwriting discounts and commissions and offering expenses. Concurrently, we completed the public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025. The net proceeds from this offering were $291.0 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and Europe, funding of our development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months. Until we can generate a sufficient amount of revenue from Rubraca, we expect to finance our operations in part through additional public or private equity or debt offerings and may seek additional capital through arrangements with strategic partners or from other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.

~~Table of Contents~~

~~Product License Agreements~~

~~Rucaparib~~

In June 2011, we entered into a worldwide license agreement with Pfizer, Inc. to obtain exclusive global rights to develop and commercialize rucaparib, a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), used for the treatment of selected solid tumors. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the ~~terms~~Settlement Agreement in legal settlement loss within the other income (expense), net of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of rucaparib, discussed below, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense.

On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st ~~Indication in US and (ii) EMA approval of an MAA for 1~~st ~~Indication in EU, to a date that is 18 months after the date of achievement of such milestones.~~

On December 19, 2016, the FDA approved Rubraca (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. The FDA approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was made in the first quarter of 2017. The FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. We paid the $23.0 million milestone payment in June 2018.

On April 6, 2018, the FDA approved our sNDA for Rubraca as maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. This approval resulted in the obligation to pay a $15.0 million milestone payment, which we paid in April 2018.

~~These milestone payments were recognized as intangible assets and will be amortized over the estimated remaining useful life of Rubraca.~~

We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize rucaparib and we are responsible for all remaining development and commercialization costs for rucaparib. We are required to make regulatory milestone payments to Pfizer of up to an additional $31.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for rucaparib are met which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize rucaparib.

In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. AstraZeneca receives royalties on any net sales of rucaparib.

~~Table of Contents~~

~~Lucitanib~~

In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, after giving effect to the first and second amendments to the license agreement, we are required to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product candidate containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib.

During 2017, we completed the committed on-going development activities related to lucitanib and received full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expenseinsurance receivable on the Consolidated Statements of ~~Operations. Lucitanib was originally developed by Clovis~~Operations and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move the program forward. We have received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us later in 2018.

~~We are party to a product license agreement for our other drug candidate rociletinib (see our 2017 Form 10-K for additional details).~~

~~Financial Operations Overview~~

~~Revenue~~

~~Product revenue is derived from sales of our product, Rubraca, in the United States.~~ We distribute our product in the U.S. principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently sell our products to patients and healthcare providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and other discounts. Revenue is recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns (collectively, “variable considerations”). ~~Revenue from product sales are recognized when customers obtain control of our product, which occurs at a point in time, typically upon delivery to the customers.~~ ~~For further discussion of our revenue recognition policy, see Note 2,~~ ~~Summary of Significant Accounting Polices~~ ~~in the Revenue Recognition section.~~

In the three and six months ended June 30, 2018, we recorded product revenue of $23.8 million and $42.3 million, respectively, related to sales of Rubraca, which we began to commercialize on December 19, 2016. Our ability to generate revenue and become profitable depends upon our ability to successfully commercialize products. Any inability on our part to successfully commercialize Rubraca in the United States and any foreign territories where it may be approved, or any significant delay in such approvals, could have a material adverse impact on our ability to execute upon our business strategy and, ultimately, to generate sufficient revenues from Rubraca to reach or maintain profitability or sustain our anticipated levels of operations.

~~Table of Contents~~

through a separate vendor who administers the program on our behalf. It is not distributed through our specialty distributor and specialty pharmacy network. This product is neither included in the transaction price nor the variable considerations to arrive at product revenue. Manufacturing costs associated with this free product is included in selling, general and administrative expenses. In the three months ended June 30, 2018, the supply of this free drug was approximately 25% of the overall commercial supply or the equivalent of $7.9 million in commercial value. In the six months ended June 30, 2018, the supply of this free drug was approximately 24% of the overall commercial supply or the equivalent of $13.4 million in commercial value. We expect the free product percentage to continue in the mid to high 20-percent range for the remainder of 2018.

~~Cost of Sales – Product~~

~~Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales.~~

~~Cost of Sales – Intangible Asset Amortization~~

~~Research and Development Expenses~~

~~Research and development expenses consist of costs incurred for the development of our product candidates and companion diagnostics, which include:~~

~~license fees and milestone payments related to the acquisition of in-licensed products, which are reported on our Consolidated Statements of Operations as acquired in-process research and development;~~

~~employee-related expenses, including salaries, benefits, travel and share-based compensation expense;~~

~~expenses incurred under agreements with contract research organizations and investigative sites that conduct our clinical trials;~~

~~the cost of acquiring, developing and manufacturing clinical trial materials;~~

~~costs associated with non-clinical activities and regulatory operations;~~

market research, disease education and other commercial product planning activities, including the hiring of a U.S. sales and marketing and medical affairs organization in preparation for the commercial launch of rucaparib; and

~~activities associated with the development of companion diagnostics for our product candidates.~~

Research and development costs are expensed as incurred. License fees and milestone payments related to in-licensed products and technology are expensed if it is determined that they have no alternative future use. Costs for certain development activities, such as clinical trials and manufacturing of clinical supply, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors. Our research and development expenses increased in the three and six months ended June 30, 2018 compared to the same period in the prior year. Our research and development expenses will continue to increase compared to last year due to higher research and development costs for rucaparib.

~~Table of Contents~~

The following table identifies research and development and acquired in-process research and development costs on a program-specific basis for our products under development. Personnel-related costs, depreciation and share-based compensation are not allocated to specific programs, as they are deployed across multiple projects under development and, as such, are separately classified as personnel and other expenses in the table below (in thousands):

Three months ended June 30,

Six months ended June 30,


2018

2017

2018

2017

(in thousands)

Rucaparib Expenses

Research and development

$
33,049

$
16,980

$
57,556

$
31,490

Rucaparib Total

33,049

16,980

57,556

31,490

Lucitanib Expenses

Research and development (a)

218

(13)

227

(99)

Lucitanib Total

218

(13)

227

(99)

Rociletinib Expenses

Research and development

$
579

$
1,528

1,594

4,719

Rociletinib Total

579

1,528

1,594

4,719

Personnel and other expenses

18,861

14,613

36,873

29,445

Total

$
52,707

$
33,108

$
96,250

$
65,555

~~(a)This amount reflects actual costs incurred less amounts due from Servier for reimbursable development expenses pursuant to the collaboration and license agreement described in Note 12,~~ ~~License Agreements~~ ~~to our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q.~~

~~Selling, General and Administrative Expenses~~

Selling, general and administrative expenses consist principally of salaries and related costs for personnel in executive, commercial, finance, legal, investor relations, human resources, and information technology functions. Other selling, general and administrative expenses include facilities expenses, communication expenses, information technology costs, corporate insurance and professional fees for legal, consulting and accounting services. With the FDA approval of Rubraca on December 19, 2016, all sales and marketing expenses associated with Rubraca are included in selling, general and administrative expenses. Our selling, general and administrative expenses will continue to increase compared to last year in support of our commercial activities related to Rubraca in the United States and Europe.

~~Acquired In-Process Research and Development Expenses~~

Acquired in-process research and development expenses consist of upfront payments to acquire a new drug compound, as well as subsequent milestone payments. Acquired in-process research and development payments are immediately expensed provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use. Once regulatory approval is received, payments to acquire rights, and the related milestone payments, are capitalized and the amortization of such assets recorded to intangible asset amortization cost of sales.

~~Other Income and Expense~~

Other income and expense is primarily comprised of foreign currency gains and losses resulting from transactions with contract research organizations (“CROs”), investigational sites and contract manufacturers where payments are made in currencies other than the U.S. dollar. Other expense also includes interest expense recognized related to our convertible senior notes.

~~Critical Accounting Policies and Significant Judgments and Estimates~~

~~Table of Contents~~

including those related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For a description of our critical accounting policies, please see Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Other than the change to our revenue recognition policy discussed in Note 2, ~~Summary of Significant Accounting Policies, there have not been any material changes to our critical accounting policies since December 31, 2017.~~

~~New Accounting Standards~~

From time to time, the Financial Accounting Standards Board (“FASB”) or other standards-setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through the issuance of an Accounting Standards Update. Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our Consolidated Financial Statements upon adoption.

~~To understand the impact of recently issued guidance, whether adopted or to be adopted, please review the information provided in Note 2,~~ ~~Summary of Significant Accounting Policies, in the Notes to the Unaudited Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.~~

~~Results of Operations~~

~~Comparison of Three Months Ended June 30, 2018 and 2017:~~

~~The following table summarizes the results of our operations for the three months ended June 30, 2018 and 2017 (in thousands):~~

Change

Three months ended June 30,

Favorable/(Unfavorable)


2018

2017

$

%

Product revenue

$
23,757

$
14,620

$
9,137

62
%
Operating expenses:

Cost of sales - product

4,490

2,730

(1,760)

(64)
%
Cost of sales - intangible asset amortization

709

372

(337)

(91)
%
Research and development

52,707

33,108

(19,599)

(59)
%
Selling, general and administrative

44,864

36,149

(8,715)

(24)
%
Total expenses

102,770

72,359

(30,411)

(42)
%
Operating loss

(79,013)

(57,739)

(21,274)

(37)
%
Other income (expense):

Interest expense

(3,581)

(2,598)

(983)

(38)
%
Foreign currency (loss) gain

(104)

76

(180)

(237)
%
Legal settlement loss

—

(117,000)

117,000

100
%
SEC settlement costs reserve

(20,000)

—

(20,000)

(100)
%
Other income

1,475

594

881

148
%
Other expense, net

(22,210)

(118,928)

96,718

81
%
Loss before income taxes

(101,223)

(176,667)

75,444

43
%
Income tax benefit

33

1,281

(1,248)

(97)
%
Net loss

$
(101,190)

$
(175,386)

$
74,196

42
%

~~Product Revenue.~~ Product revenue for the three months ended June 30, 2018 increased compared to the same period in the prior year primarily due to continued growth in sales of Rubraca, which was approved for sale in the United States markets and we began shipping on December 19, 2016. Product revenue is recorded net of variable considerations

~~Table of Contents~~

comprised of rebates, chargebacks and other discounts. Variable considerations represented approximately 9.9% and 7.9% of the transaction price recognized in the three months ended June 30, 2018 and 2017, respectively, and are summarized as follows:

Three months ended

Three months ended


June 30, 2018

June 30, 2017

$

% of Gross Sales

$

% of Gross Sales

(in thousands)

(in thousands)

Transaction price

$
26,390

100.0%

$
15,876

100.0%
Variable considerations:

Government rebates and chargebacks

1,583

5.9%

635

4.0%
Discounts and fees

1,050

4.0%

621

3.9%
Total variable considerations

2,633

9.9%

1,256

7.9%
Product revenue

$
23,757

90.1%

$
14,620

92.1%

~~Cost of Sales – Product.~~ Product cost of sales for the three months ended June 30, 2018 increased compared to the same period in the prior year primarily due to the increase in product revenue. Product cost of sales primarily relate to manufacturing, freight and royalties costs associated with Rubraca sales in the period. Manufacturing costs associated with sales in the three months ended June 30, 2017 were expensed as incurred based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, and therefore, a minimal amount is included as product cost of sales. ~~These costs increased in the three months ended June 30, 2018, as we depleted these inventories as of the fourth quarter 2017.~~

~~Cost of Sales – Intangible Asset Amortization~~. In the three months ended June 30, 2018 and 2017, we recognized cost of sales of $0.7 million and $0.4 million, respectively, associated with the amortization of capitalized milestone payments related to the approvals of Rubraca by the FDA in December 2016 and April 2018 and by the European Commission in May 2018.

~~Research and Development Expenses.~~ Research and development expenses increased during the three months ended June 30, 2018 compared to the same period in the prior year primarily due to higher research and development costs for rucaparib. Clinical trial costs for rucaparib were higher compared to the same quarter a year ago due to increased enrollment in our TRITON2 and TRITON3 studies for prostate cancer. We have increased costs related to our new ATLAS study for bladder cancer and our ATHENA combination study with Bristol-Myers Squibb Company’s immunotherapy OPDIVO for ovarian cancer. In addition, personnel costs increased during the three months ended June 30, 2018 due to higher headcount.

Clinical trial costs for rociletinib were $0.9 million lower than the second quarter of 2017 primarily due to the completion of patient enrollment for all of the TIGER studies in non-small cell lung cancer.

~~Selling, General and Administrative Expenses.~~ Selling, general and administrative expenses increased during the three months ended June 30, 2018 compared to the same period in the prior year primarily due to $3.3 million higher legal expense and $3.6 million higher stock compensation expense.

~~Interest Expense.~~ ~~Interest expense increased during the three months ended June 30, 2018 compared to the same period in the prior year primarily due to the issuance of the 2025 Notes on April 19, 2018.~~

~~Legal Settlement~~Comprehensive Loss.~~During the second quarter of 2017, we recorded a one-time charge of $117.0 million related to an agreement to resolve a litigation claim against us and certain of our officers.~~

~~SEC Settlement Costs Reserve.~~ ~~During the second quarter of 2018, we recorded a one-time charge of $20.0 million related to a preliminary agreement reached with the~~ ~~SEC that, if approved by the SEC and the U.S. District Court where the settlement is filed, would~~ ~~resolve the SEC’s pending investigation. See Note 14,~~ ~~Commitments and Contingencies~~ ~~for further information regarding this investigation and other legal proceedings.~~

~~Table of Contents~~

~~Comparison of Six Months Ended June 30, 2018 and 2017:~~

~~The following table summarizes the results of our operations for the six months ended June 30, 2018 and 2017 (in thousands):~~

Change

Six months ended June 30,

Favorable/(Unfavorable)


2018

2017

$

%

Product revenue

$
42,279

$
21,665

$
20,614

95
%
Operating expenses:

Cost of sales - product

8,495

3,893

(4,602)

(118)
%
Cost of sales - intangible asset amortization

1,080

743

(337)

(45)
%
Research and development

96,250

65,555

(30,695)

(47)
%
Selling, general and administrative

84,138

65,373

(18,765)

(29)
%
Total expenses

189,963

135,564

(54,399)

(40)
%
Operating loss

(147,684)

(113,899)

(33,785)

(30)
%
Other income (expense):

Interest expense

(6,216)

(5,178)

(1,038)

(20)
%
Foreign currency loss

(185)

(83)

(102)

(123)
%
Legal settlement loss

(7,975)

(117,000)

109,025

93
%
SEC settlement costs reserve

(20,000)

—

(20,000)

(100)
%
Other income

2,883

946

1,937

205
%
Other expense, net

(31,493)

(121,315)

89,822

74
%
Loss before income taxes

(179,177)

(235,214)

56,037

24
%
Income tax benefit

292

1,365

(1,073)

(79)
%
Net loss

$
(178,885)

$
(233,849)

$
54,964

24
%

~~Product Revenue.~~ Product revenue for the six months ended June 30, 2018 increased compared to the same period in the prior year primarily due to continued growth in sales of Rubraca, which was approved for sale in the United States markets and we began shipping on December 19, 2016. Product revenue is recorded net of variable considerations comprised of rebates, chargebacks and other discounts. Variable considerations represented 10.2% and 8.9% of the transaction price recognized in the three months ended June 30, 2018 and 2017, respectively, and are summarized as follows:

Six months ended

Six months ended


June 30, 2018

June 30, 2017


$

% of Gross Sales

$

% of Gross Sales

(in thousands)

(in thousands)

Gross product revenue

$
47,091

100.0%

$
23,778

100.0%
Sales deductions:

Government rebates and chargebacks

2,963

6.3%

1,072

4.5%
Discounts and fees

1,849

3.9%

1,041

4.4%
Total sales deductions

4,812

10.2%

2,113

8.9%
Product revenue, net

$
42,279

89.8%

$
21,665

91.1%

~~Cost of Sales – Product.~~ Product cost of sales for the six months ended June 30, 2018 increased compared to the same period in the prior year primarily due to the increase in product revenue. Product cost of sales primarily relate to manufacturing, freight and royalties costs associated with Rubraca sales in the period. Manufacturing costs associated with sales in the six months ended June 30, 2017 were expensed as incurred based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, and therefore, a minimal amount is included as product cost of sales. ~~These costs increased in the six months ended June 30, 2018, as we depleted the these inventories as of the fourth quarter 2017.~~

~~Cost of Sales – Intangible Asset Amortization. In the six months ended June 30, 2018 and 2017, we recognized cost of sales of $1.1 million and $0.7 million, respectively, associated with the amortization of capitalized milestone~~

~~Table of Contents~~

~~payments related to the approvals of Rubraca by the FDA in December 2016 and April 2018 and by the European Commission in May 2018.~~

~~Research and Development Expenses.~~ Research and development expenses increased during the six months ended June 30, 2018 compared to the same period in the prior year primarily due to higher research and development costs for rucaparib. Clinical trial costs for rucaparib were higher compared to the same period a year ago due to higher costs from increased enrollment in ARIEL4, our confirmatory ovarian cancer trials, and increased enrollment in our TRITON2 and TRITON3 studies for prostate cancer. We have increased costs related to our new ATLAS study for bladder cancer, our ATHENA combination study with Bristol-Myers Squibb Company’s immunotherapy OPDIVO for ovarian cancer and our RUCA-J study for ovarian cancer in Japan. In addition, personnel costs increased during the six months ended June 30, 2018 due to higher headcount.

Clinical trial costs for rociletinib were $3.1 million lower than the six months ended June 30, 2017 primarily due to the completion of patient enrollment for all of the TIGER studies in non-small cell lung cancer.

~~Selling, General and Administrative Expenses.~~ Selling, general and administrative expenses increased during the six months ended June 30, 2018 compared to the same period in the prior year primarily due to the increase of costs associated with building out the European infrastructure in anticipation of commercialization there. In addition, there was an increase of $4.3 million in legal expense and $4.8 million in stock compensation expense.

~~Interest Expense.~~ ~~Interest expense increased during the six months ended June 30, 2018 compared to the same period in the prior year primarily due to the issuance of the 2025 Notes on April 19, 2018.~~

~~Legal Settlement Loss.~~ During the first quarter of 2018, we recorded a one-time charge of $8.0 million related to an agreement to resolve a potential litigation claim against us and our officers. During the second quarter of 2017, we recorded a one-time charge of $117.0 million related to an agreement to resolve a litigation claim against us and certain of our officers.

~~SEC Settlement Costs Reserve.~~ ~~During the second quarter of 2018, we recorded a one-time charge of $20.0 million related to a preliminary agreement reached with the~~ ~~SEC that, if approved by the SEC and the U.S. District Court where the settlement is filed, would~~ ~~resolve the SEC’s ongoing investigation. See Note 14,~~ ~~Commitments and Contingencies~~ ~~for further information regarding this investigation and other legal proceedings.~~

~~Other Income.~~ ~~Other income increased during the six months ended June 30, 2018 compared to the same period in the prior year due to interest income earned on our available-for-sale securities.~~

~~Liquidity and Capital Resources~~

To date, we have funded our operations through the public offering of our common stock and the private placement of convertible debt securities and preferred stock. In April 2018, we sold 1,837,898 shares of our common stock in a public offering at $54.41 per share. The net proceeds from the offering were $93.8 million, after deducting underwriting discounts and commissions and offering expenses. Concurrently, we completed the public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025. The net proceeds from this offering were $291.0 million, after deducting underwriting discounts and commissions and offering expenses. At June 30, 2018, we had cash, cash equivalents and available-for-sale securities totaling $682.2 million.

~~The following table sets forth the primary sources and uses of cash for the six months ended June 30, 2018 and 2017 (in thousands):~~

Six months ended June 30,

2018

2017

Net cash used in operating activities

$
(210,844)

$
(149,541)

Net cash used in investing activities

(172,208)

(133,864)

Net cash provided by financing activities

387,382

558,440

Effect of exchange rate changes on cash and cash equivalents

(207)

565

Net increase in cash and cash equivalents

$
4,123

$
275,600

~~Table of Contents~~

~~Operating Activities~~

Net cash used in operating activities for all periods resulted primarily from our net losses adjusted for non-cash items and changes in components of working capital. Net cash used in operating activities was higher during the six months ended June 30, 2018 compared to the same period in the prior year due to a higher net loss as adjusted for non-cash items and increases in the operating assets needed to support the commercialization of Rubraca, most notably related to inventory.

~~Investing Activities~~

Net cash used in investing activities for the six months ended June 30, 2018 includes net purchases of available-for-sale securities of $115.0 million and milestone payments of $55.0 million. Net cash used in investing activities in the same period in the prior year was mainly the result of net purchases of available-for-sale securities of $130.0 million in that period.

~~Financing Activities~~

Net cash provided by financing activities for the six months ended June 30, 2018 and 2017 includes $2.6 million and $12.3 million, respectively, received from employee stock option exercises. We completed the sale of $93.8 million and $546.2 million of common stock, net of issuance costs, respectively, during the six months ended June 30, 2018 and June 30, 2017. In addition, we issued $291.0 million of convertible senior notes, net of issuance costs during the six months ended June 30, 2018.

~~Operating Capital Requirements~~

We expect to incur significant losses for the foreseeable future, as we commercialize Rubraca and expand our selling, general and administrative functions to support the growth in our commercial organization. Additionally, our operating plan for the remainder of 2018 includes a significant investment in inventory to meet the projected commercial requirements for Rubraca. We receive the active pharmaceutical ingredient in Rubraca from one supplier and we experience long lead times associated with its production. Accordingly, we expect to experience a decrease in our liquidity at the beginning of a production cycle and an increase as the inventory produced is sold through.

~~As of June 30, 2018, we had cash, cash equivalents and available-for-sale securities totaling $682.2 million and total current liabilities of $76.6 million.~~ In April 2018, we sold 1,837,898 shares of our common stock in a public offering at $54.41 per share. The net proceeds from the offering were $93.8 million, after deducting underwriting discounts and commissions and offering expenses. Concurrently, we completed the public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025. The net proceeds from this offering were $291.0 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and Europe, funding of our development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months.

Our product supply costs will be approximately $10 million for the remainder of 2018. These costs reflect our plan to produce additional inventory in advance of the transition to a new manufacturing facility for Rubraca. We will also incur final capital costs for the new manufacturing facility of approximately $8 million in late 2018.

Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including but not limited to:

~~the number and characteristics of the product candidates, companion diagnostics and indications we pursue;~~

~~the achievement of various development, regulatory and commercial milestones resulting in required payments to partners pursuant to the terms of our license agreements;~~

~~the scope, progress, results and costs of researching and developing our product candidates and related companion diagnostics and conducting clinical and non-clinical trials;~~

~~Table of Contents~~

~~the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates and companion diagnostics;~~

~~the cost of commercialization activities, including marketing and distribution costs;~~

~~the cost of manufacturing any of our product candidates we successfully commercialize;~~

~~the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and outcome of such litigation; and~~

~~the timing, receipt and amount of sales, if any, of our product candidates.~~

~~Contractual Obligations and Commitments~~

For a discussion of our contractual obligations, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2017 Annual Report on Form 10-K. Other than the milestone payment to Pfizer triggered on April 6, 2018 upon the FDA’s approval of our sNDA for Rubraca as maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, there have not been any material changes to such contractual obligations or potential milestone payments since December 31, 2017. For further information regarding our contractual obligations and commitments, see Note 14, ~~Commitments and Contingencies~~ ~~to our unaudited consolidated financial statements included elsewhere in this report.~~

~~ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~

We are exposed to market risk related to changes in interest rates. As of June 30, 2018, we had cash, cash equivalents and available-for-sale securities of $682.2 million, consisting of bank demand deposits, money market funds and U.S. treasury securities. The primary objectives of our investment policy are to preserve principal and maintain proper liquidity to meet operating needs. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Our available-for-sale securities are subject to interest rate risk and will decline in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our portfolio.

We contract with contract research organizations, investigational sites and contract manufacturers globally where payments are made in currencies other than the U.S. dollar. In addition, on October 3, 2016, we entered into a Manufacturing and Services Agreement with a Swiss company for the production and supply of the active ingredient for Rubraca. Under the terms of this agreement, payments for the supply of the active ingredient in Rubraca as well as scheduled capital program fee payment toward capital equipment and other costs associated with the construction of a dedicated production train will be made in Swiss francs. Once the production facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the agreement, which expires on December 31, 2025.

As of June 30, 2018, $147.8 million of purchase commitments exist under the Swiss Manufacturing and Services Agreement and we are required to remit amounts due in Swiss francs. Due to other variables that may exist, it is difficult to quantify the impact of a particular change in exchange rates. However, we estimate that if the value of the US dollar was to strengthen by 10% compared to the value of Swiss franc as of June 30, 2018, it would decrease the total US dollar purchase commitment under the Swiss Manufacturing and Services Agreement by $16.0 million. Similarly, a 10% weakening of the US dollar compared to the Swiss franc would increase the total US dollar purchase commitment by $13.3 million.

While we periodically hold foreign currencies, primarily Euro, Swiss Franc and Pound Sterling, we do not use other financial instruments to hedge our foreign exchange risk. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. As of both June 30, 2018 and December 31, 2017, approximately 1% of our total liabilities were denominated in currencies other than the functional currency.

~~Table of Contents~~

~~ITEM 4.CONTROLS AND PROCEDURES~~

~~Disclosure Controls and Procedures~~

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (“Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. With the participation of our Chief Executive Officer and Principal Financial and Accounting Officer, management performed an evaluation as of June 30, 2018 of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and Principal Financial and Accounting Officer concluded that, as of June 30, 2018, our disclosure controls and procedures were effective at the reasonable assurance level.

~~Changes in Internal Control over Financial Reporting~~

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

~~Table of Contents~~

~~PART II. OTHER INFORMATION~~

~~ITEM 1.LEGAL PROCEEDINGS~~

~~Rociletinib-Related Litigation~~

Following Clovis’ regulatory announcement in November 2015 of adverse developments in its ongoing clinical trials for rociletinib, Clovis and certain of its current and former executives were named in various securities lawsuits, the largest of which was a putative class action lawsuit in the District of Colorado (the “Medina Action”) which was settled on October 26, 2017 (the “Medina Settlement”). The open actions currently pending against Clovis are discussed below.

On November 10, 2016, Antipodean Domestic Partners (“Antipodean”) filed a complaint (the “Antipodean Complaint”) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleges that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the offering materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages. On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Antipodean Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint.

On January 31, 2017, the defendants filed a motion to stay the Antipodean action pending resolution of the Medina Action in the District of Colorado. On March 14, 2017, the Clovis defendants and Antipodean participated in a mediation, which did not result in a settlement.

On March 29, 2017, the defendants filed a motion to dismiss the Antipodean Amended Complaint. On August 8, 2017, Justice Masley of the New York Supreme Court, County of New York granted the defendants’ motion to stay. Per the Court’s August 10, 2017 order, the defendants’ motion to dismiss was held in abeyance and deemed submitted on November 1, 2017. On November 1, 2017, the defendants provided a status update to the Court regarding the outcome of the hearing. The update informed the Court that Antipodean had excluded itself from the Medina Settlement, as memorialized in the final judgment entered by the Medina Court.

~~On May 2, 2018, the Court issued an order denying the defendants’ motion to dismiss. Defendants filed an answer to the Antipodean Amended Complaint on June 6, 2018.~~

~~The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint. However, there can be no assurance that the defense will be successful.~~

In March 2017, two putative shareholders of the Company, Macalinao and McKenry (the “Derivative Plaintiffs”), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”).

~~Table of Contents~~

While the motion to dismiss remained pending, on November 19, 2018, Plaintiffs filed a motion for leave to file a supplemental consolidated complaint, and on November 20, 2018, the ~~defendants’~~Court granted that motion. On November 27, 2018, Plaintiffs filed their supplemental complaint (the “Supplemental Derivative Complaint”), which adds allegations concerning the Company’s, Mr. Mahaffy’s and Mr. Mast’s settlements with the United States Securities and Exchange Commission. Pursuant to a briefing schedule entered by the Court, the defendants filed a supplemental motion to dismiss the ~~Consolidated~~Supplemental Derivative Complaint ~~has been scheduled for~~on February 4,6, 2019; plaintiffs filed an opposition brief on February 22, 2019; and the defendants filed a reply brief on March 5, 2019. The Court held oral arguments on the defendants’ motions to dismiss on June 19, 2019. At the oral arguments, the Court ordered the parties to submit supplemental letter briefs on the motion to dismiss; plaintiffs filed their letter brief on June 25, 2019 and the defendants filed theirs on July 1, 2019.

Table of Contents

The Company intends to vigorously defend against the allegations in the ~~Consolidated~~Supplemental Derivative Complaint, but there can be no assurance that the defense will be successful.

On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the “Guo Complaint”) against certain officers and directors of the Company in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company’s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages.

On June 19, 2017, the parties filed a joint motion to stay the Guo action pending resolution of the motion to dismiss the Consolidated Derivative Complaint. On June 20, 2017, the court granted the motion to stay.

The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful.

~~Table of Contents~~

~~Director Compensation Litigation~~

European Patent Opposition

Two oppositions were filed in the granted European counterpart of the rucaparib camsylate salt/polymorph patent on June 20, 2017. The ~~grounds~~European Patent Office’s Opposition Division held an oral hearing on December 4, 2018, during which it upheld claims, narrowed from the originally granted patent, to certain crystalline forms of ~~opposition~~rucaparib camsylate, including, but not limited to, rucaparib S-camsylate Form A, the crystalline form in Rubraca. On February 4, 2019, the Opposition Division issued a written decision confirming its decision at the oral hearing. In June 2019, Clovis and one opponent, Hexal, filed briefs appealing the written decision of the European Opposition Division and responses to the appeal briefs are due by November 4, 2019.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Information

This Quarterly Report on Form 10-Q and the information incorporated herein by reference includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the market acceptance and commercial viability of our approved product, the development of our sales and marketing capabilities, the performance of our clinical trial partners, third party manufacturers and our diagnostic partners, our ongoing and planned non-clinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, including our ability to confirm clinical benefit of our approved product through confirmatory trials and other post-marketing requirements, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, expectations regarding sales of our products, our results of operations, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate, including our competition and the trends that may affect the industry or us.

Table of Contents

Clovis Oncology®, the Clovis logo and Rubraca® are trademarks of Clovis Oncology, Inc. in the United States and in other selected countries. All other brand names or trademarks appearing in this report are the property of their respective holders. Unless the context requires otherwise, references in this report to “Clovis,” the “Company,” “we,” “us” and “our” refer to Clovis Oncology, Inc., together with its consolidated subsidiaries.

Overview

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.

Our product Rubraca® (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (“PARP”), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The initial indication received approval from the United States Food and Drug Administration (“FDA”) in December 2016 and covers the treatment of adult patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. In April 2018, the FDA also approved Rubraca for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The approval in this second, broader and earlier-line indication on a priority review timeline was based on positive data from the phase 3 ARIEL3 clinical trial. Diagnostic testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

In May 2018, the European Commission granted a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum-based chemotherapy, and who are unable to tolerate further platinum-based chemotherapy. As this is a conditional approval, it will be necessary to complete certain confirmatory post marketing commitments. In January 2019, the European Commission granted a variation to the marketing authorization to include the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. With this approval, Rubraca is now authorized in the EU for certain patients in the recurrent ovarian cancer maintenance setting regardless of their BRCA mutation status. Rubraca was the first PARP inhibitor licensed for an ovarian cancer treatment indication in the EU and is now the first to be authorized for both treatment and maintenance treatment among eligible patients with ovarian cancer. We completed our launch of Rubraca as maintenance therapy in Germany and the United Kingdom in March 2019 and we plan to launch in other EU countries during 2019 and 2020.

Beyond our initial labeled indication, we have a robust Rubraca clinical development program underway to further evaluate Rubraca in a variety of solid tumor types, either as monotherapy or in combination with other agents, including several studies as part of our ongoing clinical collaboration with Bristol-Myers Squibb Company to evaluate its immunotherapy OPDIVO® (nivolumab) in combination with Rubraca. We hold worldwide rights for Rubraca.

The initial TRITON2 data presented at ESMO 2018 demonstrated a 44% confirmed objective response rate by investigator assessment in 25 RECIST/PCWG3 response-evaluable patients with a BRCA1/2 alteration. The median duration of response in these patients had not yet been reached at time of presentation. In addition, a 51% confirmed

Table of Contents

prostate-specific antigen (“PSA”) response rate was observed in 45 PSA response-evaluable patients with a BRCA1/2 alteration. In August 2019, we plan to provide an update to the FDA on the TRITON2 data for patients with BRCA-mutant mCRPC, and the data includes response rates consistent with those shown at ESMO 2018. In the initial TRITON2 data presented at ESMO 2018, the most common treatment-emergent adverse events (“TEAEs”) of any grade (CTCAE Grade 1-4) in all patients regardless of causality included asthenia/fatigue (44.7%, or 38/85), nausea (42.4%, or 36/85), anemia/decreased hemoglobin (28.2%, or 24/85), decreased appetite (28.2%, or 24/85) and constipation (22.4%, or 19/85). Five patients (5.9%) discontinued therapy due to a non-progression TEAE. One patient died due to disease progression. Safety data for Rubraca in men with mCRPC continues to be consistent with those observed in patients with ovarian cancer and other solid tumors.

In April 2019, we discontinued our sponsored Phase 2 open-label monotherapy clinical trial evaluating rucaparib in recurrent, metastatic bladder cancer (CO-338-085 (“ATLAS”)). The decision was based on the recommendation from a data monitoring committee (“DMC”) following its review of preliminary efficacy data for 62 patients enrolled and treated in the study, which demonstrated that the objective response rate in the intent-to-treat population did not meet the protocol-defined continuance criteria, and suggested that treatment with monotherapy rucaparib may not provide a meaningful clinical benefit to patients. Therefore, the DMC recommended to stop enrollment to the study, and we decided to terminate the ATLAS trial early. The recommendation of the DMC was not based on the safety profile of rucaparib in this study population.

We are continuing to evaluate the potential for rucaparib in combination with other agents for the treatment of a variety of solid tumors. Our planned Phase 2 pan-tumor study in patients with solid tumors associated with deleterious mutations in homologous recombination repair genes is expected to begin by year-end 2019.

In June 2011, we obtained an exclusive, worldwide license from Pfizer to develop and commercialize rucaparib. In April 2012, we obtained an exclusive license from AstraZeneca under a family of patents and patent applications which permits the development and commercialization of rucaparib for certain methods of treating patients with PARP inhibitors. U.S. Patent 6,495,541 directed to the rucaparib composition of matter and its equivalent counterparts issued in dozens of countries, expires in 2020 and are potentially eligible for up to five years patent term extension in various jurisdictions. We believe that patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the “Hatch-Waxman Act”) could be available to extend our patent exclusivity for rucaparib to the fourth quarter of 2023 in the United States. Additionally, other patents and patent applications are directed to methods of making, methods of using, dosing regimens, various salt and polymorphic forms and formulations and have expiration dates ranging from 2020 through potentially 2035, including the rucaparib camsylate salt/polymorph patent family licensed from Pfizer, which expires in 2031 and a patent family directed to high dosage strength rucaparib tablets that expires in 2035. As of 2019, the rucaparib camsylate salt/polymorph patent was issued in 49 countries to date (including US and Europe), with applications pending in 9 countries, the rucaparib composition of matter patent was issued in 48 countries and the high dosage strength rucaparib tablets patent was issued in the U.S. and is pending in Europe and in 14 countries. Two oppositions were filed in the granted European counterpart of the rucaparib camsylate salt/polymorph patent on June 20, 2017. European oppositions are commonly filed against patents related to ~~Rubraca were lack of novelty and lack of inventive step. A preliminary opinion and summons to oral proceedings were issued on April 4, 2018.~~pharmaceutical products. The European Patent Office’s Opposition Division held an oral hearing ~~is scheduled for~~on December 4, ~~2018. The preliminary opinion provides~~2018, during which it upheld claims, narrowed from the originally granted patent, to certain crystalline forms of rucaparib camsylate, including, but not limited to, rucaparib S-camsylate Form A, the crystalline form in Rubraca. On February 4, 2019, the Opposition Division issued a ~~non-binding indication~~written decision confirming its decision at the oral hearing. In June 2019, Clovis and one opponent, Hexal, filed briefs appealing the written decision of the ~~tribunal’s view. In~~European Opposition Division and responses to the ~~preliminary opinion, the tribunal agree with some of our positions and agree with certain objections made~~appeal briefs are due by ~~the opponents. As part of the proceeding, we have the opportunity to submit further argument and pursue alternative~~November 4, 2019. All claims in the ~~form~~originally granted patent will remain in force until the Technical Board of auxiliary requests. While the ultimate results of patent challenges can be difficult to predict, we believe a number of factors, including a constellation of unexpected properties, support the novelty and non-obviousness of ourAppeal issues its decision. The rucaparib camsylate salt/polymorph ~~composition~~patent expires in 2031. We have filed for patent term extension under a supplementary protection certificate for Rubraca in the European counterpart of ~~matter patent.~~the rucaparib camsylate salt/polymorph patent and believe that extension could be available to 2033. Patents in our high dosage strength rucaparib tablets patent family issued in the United States, with claims that cover the commercial Rubraca product, including all commercial dosage strengths expire in 2035. Additionally, in Europe, regulatory exclusivity is available for ten years, plus one year for a new indication, therefore, we have regulatory exclusivity for Rubraca in Europe until 2028, and if an additional indication is approved, until 2029.

In addition to Rubraca, we have one other product candidate. Lucitanib is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). We believe that recent data for a drug similar to lucitanib that inhibits these same pathways – when combined with a PD-1

Table of Contents

inhibitor – represent a scientific rationale for development of lucitanib in combination with a PD-1 inhibitor, and a Clovis-sponsored study of lucitanib in combination with nivolumab is underway in advanced gynecologic cancers and other solid tumors. In addition, we have initiated a study of lucitanib in combination with Rubraca in ovarian cancer, based on encouraging data of VEGF and PARP inhibitors in combination. Each of these Phase 1b/2 studies is currently enrolling patients. We hold the global development and commercialization rights (except for China) for lucitanib.

~~ITEM 1A.RISK FACTORS~~

We have never been profitable and, as of June 30, 2019, we had an accumulated deficit of $2,049.9 million. We incurred net losses of $206.9 million and $178.9 million for the six months ended June 30, 2019 and 2018, respectively. We had cash, cash equivalents and available-for-sale securities totaling $315.9 million at June 30, 2019.

We have principally funded our operations using the net proceeds from the sale of convertible preferred stock, the issuance of convertible promissory notes, public offerings of our common stock and our convertible senior notes offering. We expect to incur significant losses for the foreseeable future, as we incur costs related to commercial activities associated with Rubraca. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months. Until we can generate a sufficient amount of revenue from Rubraca, we expect to finance our operations in part through additional public or private equity or debt offerings and may seek additional capital through arrangements with strategic partners or from other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.

License Agreements

Rucaparib

In June 2011, we entered into a worldwide license agreement with Pfizer, Inc. to obtain exclusive global rights to develop and commercialize Rubraca. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of Rubraca, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense.

On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st Indication in US and (ii) EMA approval of an MAA for 1st Indication in EU, to a date that is 18 months after the date of achievement of such milestones.

On December 19, 2016, Rubraca received its initial FDA approval. This approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was paid in the first quarter of 2017. This FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. We paid the $23.0 million milestone payment in June 2018.

On April 6, 2018, Rubraca received a second FDA approval. This approval resulted in an obligation to pay a $15.0 million milestone payment, which we paid in April 2018.

Table of Contents

In May 2018, Rubraca received its initial European Commission approval. This approval resulted in an obligation to pay a $20.0 million milestone payment, which we paid in June 2018.

In January 2019, Rubraca received its second European Commission approval. This approval resulted in an obligation to pay a $15.0 million milestone payment, which we paid in February 2019.

In June 2019, we paid a $0.75 million milestone payment due to the launch of Rubraca as maintenance therapy in Germany in March 2019.

These milestone payments were recognized as intangible assets and will be amortized over the estimated remaining useful life of Rubraca.

We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize Rubraca and we are responsible for all remaining development and commercialization costs for Rubraca. We are required to make regulatory milestone payments to Pfizer of up to an additional $16.0 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for Rubraca are met, which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize Rubraca.

In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with Rubraca under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of Rubraca for the uses claimed by these patents. AstraZeneca receives royalties on any net sales of Rubraca.

Lucitanib

In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, after giving effect to the first and second amendments to the license agreement, we are required to pay to Advenchen 25% of any consideration, excluding royalties, we receive from sublicensees, in lieu of the milestone obligations set forth in the agreement. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product candidate containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib.

Table of Contents

During 2017, we completed the committed on-going development activities related to lucitanib and received full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations and Comprehensive Loss. Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move the program forward. We received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us during October 2018.

Pursuant to terms of each of our product license agreements, we will pay royalties to our licensors on sales, if any, of the respective products.

Rociletinib

In May 2010, we entered into an exclusive worldwide license agreement with Celgene to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor (“EGFR”) gene product. Rociletinib, an oral mutant-selective inhibitor of EGFR, was identified as the lead inhibitor candidate under the license agreement. Following the termination of enrollment in all sponsored clinical studies of rociletinib, we provided notice of termination to Celgene of our license rights to rociletinib, an oral mutant-selective inhibitor of EGFR, and that termination became effective in the second quarter of 2019.

Financial Operations Overview

Revenue

Product revenue is derived from sales of our product, Rubraca, in the United States and the EU. We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently sell our products to patients and healthcare providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and other discounts. Revenue is recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns (collectively, “variable considerations”). Revenue from product sales are recognized when customers obtain control of our product, which occurs at a point in time, typically upon delivery to the customers. For further discussion of our revenue recognition policy, see Note 2, Summary of Significant Accounting Polices in the Revenue Recognition section.

In the three and six months ended June 30, 2019, we recorded product revenue of $33.0 million and $66.1 million, respectively, related to sales of Rubraca, which we began to commercialize on December 19, 2016. Our ability to generate revenue and become profitable depends upon our ability to successfully commercialize products. Any inability on our part to successfully commercialize Rubraca in the United States, the EU and any foreign territories where it may be approved, or any significant delay in such approvals, could have a material adverse impact on our ability to execute upon our business strategy and, ultimately, to generate sufficient revenues from Rubraca to reach or maintain profitability or sustain our anticipated levels of operations.

We supply commercially labeled Rubraca free of charge to eligible patients who qualify due to financial need through our patient assistance program and the majority of these patients are on Medicare. This product is distributed through a separate vendor who administers the program on our behalf. It is not distributed through our specialty distributor and specialty pharmacy network. This product is neither included in the transaction price nor the variable considerations to arrive at product revenue. Manufacturing costs associated with this free product is included in selling, general and administrative expenses. For the six months ended June 30, 2019, the supply of this free drug was approximately 21% of the overall commercial supply or the equivalent of $17.7 million in commercial value.

Cost of Sales – Product

Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales.

Table of Contents

Cost of Sales – Intangible Asset Amortization

Research and Development Expenses

Research and development expenses consist of costs incurred for the development of our product candidates and companion diagnostics, which include:

●

license fees and milestone payments related to the acquisition of in-licensed products, which are reported on our Consolidated Statements of Operations and Comprehensive Loss as acquired in-process research and development;

●

employee-related expenses, including salaries, benefits, travel and share-based compensation expense;

●

expenses incurred under agreements with contract research organizations (“CROs”) and investigative sites that conduct our clinical trials;

●

the cost of acquiring, developing and manufacturing clinical trial materials;

●

costs associated with non-clinical activities and regulatory operations;

●

market research, disease education and other commercial product planning activities; and

●

activities associated with the development of companion diagnostics for our product candidates.

Research and development costs are expensed as incurred. License fees and milestone payments related to in-licensed products and technology are expensed if it is determined that they have no alternative future use. Costs for certain development activities, such as clinical trials and manufacturing of clinical supply, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors. Our research and development expenses increased in the three and six months ended June 30, 2019 compared to the same period in the prior year. We expect research and development costs to be higher for the full year 2019 compared to 2018. Thereafter, we expect research and development costs to flatten, and then trend lower in the following years, as the largest of our sponsored clinical trials near completion.


	Three months ended June 30,				Six months ended June 30,
	2019		2018		2019		2018
	(in thousands)
Rucaparib Expenses
Research and development	$	47,377	$	33,049	$	85,530	$	57,556
Rucaparib Total		47,377		33,049		85,530		57,556
Lucitanib Expenses
Research and development		1,281		218		1,601		227
Lucitanib Total		1,281		218		1,601		227
Rociletinib Expenses
Research and development	$	175	$	579		525		1,594
Rociletinib Total		175		579		525		1,594
Personnel and other expenses		21,913		18,861		45,121		36,873
Total	$	70,746	$	52,707	$	132,777	$	96,250

Selling, General and Administrative Expenses

Table of Contents

general and administrative expenses include facilities expenses, communication expenses, information technology costs, corporate insurance and professional fees for legal, consulting and accounting services. With the FDA approval of Rubraca on December 19, 2016, all sales and marketing expenses associated with Rubraca are included in selling, general and administrative expenses. We expect selling, general and administrative costs to be higher for the full year 2019 compared to 2018; however, these costs will continue to increase modestly as we prepare for anticipated product launches in a greater number of countries outside of the U.S. and launch activities for the anticipated prostate indication approval in 2020.

Acquired In-Process Research and Development Expenses

Other Income and Expense

Other income and expense is primarily comprised of foreign currency gains and losses resulting from transactions with CROs, investigative sites and contract manufacturers where payments are made in currencies other than the U.S. dollar. Other expense also includes interest expense recognized related to our convertible senior notes.

Critical Accounting Policies and Significant Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, revenue and related disclosures. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For a description of our critical accounting policies, please see Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018. Other than the adoption of the new lease standard discussed in Note 2, Summary of Significant Accounting Policies, there have not been any material changes to our critical accounting policies since December 31, 2018.

New Accounting Standards

To understand the impact of recently issued guidance, whether adopted or to be adopted, please review the information provided in Note 2, Summary of Significant Accounting Policies, in the Notes to the Unaudited Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

Table of Contents

Results of Operations

Comparison of Three Months Ended June 30, 2019 and 2018:

The following table summarizes the results of our operations for the three months ended June 30, 2019 and 2018 (in thousands):


					Change
	Three months ended June 30,				Favorable/(Unfavorable)
	2019		2018		$		%
Revenues:
Product revenue	$	32,978	$	23,757	$	9,221		39	%
Operating expenses:
Cost of sales - product		6,445		4,490		(1,955)		(44)	%
Cost of sales - intangible asset amortization		1,217		709		(508)		(72)	%
Research and development		70,746		52,707		(18,039)		(34)	%
Selling, general and administrative		48,029		44,864		(3,165)		(7)	%
Total expenses		126,437		102,770		(23,667)		(23)	%
Operating loss		(93,459)		(79,013)		(14,446)		(18)	%
Other income (expense):
Interest expense		(3,817)		(3,581)		(236)		(7)	%
Foreign currency loss		(226)		(104)		(122)		(117)	%
Legal settlement loss		(25,000)		(20,000)		(5,000)		(25)	%
Other income		1,899		1,475		424		29	%
Other expense, net		(27,144)		(22,210)		(4,934)		(22)	%
Loss before income taxes		(120,603)		(101,223)		(19,380)		(19)	%
Income tax benefit		176		33		143		433	%
Net loss	$	(120,427)	$	(101,190)	$	(19,237)		(19)	%

Product Revenue. Product revenue for the three months ended June 30, 2019 increased compared to the same period in the prior year primarily due to continued growth in sales of Rubraca, which is approved for sale in the United States and EU markets. We completed our launch of Rubraca as maintenance therapy in Germany and the UK in March 2019. Product revenue is recorded net of variable considerations comprised of rebates, chargebacks and other discounts. Product revenue for the three months ended June 30, 2019 was $32.7 million in the United States and $0.3 million outside of the United States. Variable considerations represented approximately 14.2% and 9.9% of the transaction price recognized in the three months ended June 30, 2019 and 2018, respectively. This increase is spread amongst several variable considerations; in addition, our launch of Rubraca in Germany and the UK in March 2019 contributed to the increase. Amounts are summarized as follows:


	Three months ended				Three months ended
	June 30, 2019				June 30, 2018
	$		% of Gross Sales		$		% of Gross Sales
	(in thousands)				(in thousands)

Transaction price	$	38,453		100.0%	$	26,390		100.0%
Variable considerations:
Government rebates and chargebacks		3,514		9.1%		1,583		5.9%
Discounts and fees		1,961		5.1%		1,050		4.0%
Total variable considerations		5,475		14.2%		2,633		9.9%
Product revenue	$	32,978		85.8%	$	23,757		90.1%

Cost of Sales – Product. Product cost of sales for the three months ended June 30, 2019 increased compared to the same period in the prior year primarily due to the increase in product revenue. Product cost of sales primarily relate to manufacturing, freight and royalties costs associated with Rubraca sales in the period.

Cost of Sales – Intangible Asset Amortization. In the three months ended June 30, 2019 and 2018, we recognized cost of sales of $1.2 million and $0.7 million, respectively, associated with the amortization of capitalized milestone payments related to the approvals of Rubraca by the FDA and the European Commission.

Table of Contents

Research and Development Expenses. Research and development expenses increased during the three months ended June 30, 2019 compared to the same period in the prior year primarily due to higher research and development costs for rucaparib. Clinical trial costs for rucaparib were higher compared to the same period a year ago primarily due to increased costs related to our ATHENA combination study with Bristol-Myers Squibb Company’s immunotherapy OPDIVO for ovarian cancer. In addition, personnel costs increased during the three months ended June 30, 2019 due to higher headcount to support increased rucaparib clinical trial activities.

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased during the three months ended June 30, 2019 compared to the same period in the prior year primarily due to increased commercialization activities for Rubraca and the increase of costs associated with building out the European infrastructure with the commercialization that occurred on March 1, 2019. This includes an increase of $1.7 million in personnel costs.

Interest Expense. Interest expense increased during the three months ended June 31, 2019 compared to the same period in the prior year primarily due to the issuance of the 2025 Notes on April 19, 2018.

Legal Settlement Loss. During the second quarter of 2018, we recorded a one-time charge of $20.0 million related to an agreement reached with the SEC to resolve its investigation. During the second quarter of 2019, we recorded a one-time charge of $25.0 million to settle the Antipodean Complaint. See Note 15, Commitments and Contingencies for further information regarding this complaint and other legal proceedings.

Other Income. Other income increased during the three months ended June 30, 2019 compared to the same period in the prior year due to interest income earned on our available-for-sale securities.

Comparison of Six Months Ended June 30, 2019 and 2018:

The following table summarizes the results of our operations for the six months ended June 30, 2019 and 2018 (in thousands):


					Change
	Six months ended June 30,				Favorable/(Unfavorable)
	2019		2018		$		%
Revenues:
Product revenue	$	66,096	$	42,279	$	23,817		56	%
Operating expenses:
Cost of sales - product		13,851		8,495		(5,356)		(63)	%
Cost of sales - intangible asset amortization		2,337		1,080		(1,257)		(116)	%
Research and development		132,777		96,250		(36,527)		(38)	%
Selling, general and administrative		95,791		84,138		(11,653)		(14)	%
Total expenses		244,756		189,963		(54,793)		(29)	%
Operating loss		(178,660)		(147,684)		(30,976)		(21)	%
Other income (expense):
Interest expense		(7,407)		(6,216)		(1,191)		(19)	%
Foreign currency loss		(419)		(185)		(234)		(126)	%
Legal settlement loss		(25,000)		(27,975)		2,975		11	%
Other income		4,300		2,883		1,417		49	%
Other expense, net		(28,526)		(31,493)		2,967		9	%
Loss before income taxes		(207,186)		(179,177)		(28,009)		(16)	%
Income tax benefit		336		292		44		15	%
Net loss	$	(206,850)	$	(178,885)	$	(27,965)		(16)	%

Product Revenue. Product revenue for the six months ended June 30, 2019 increased compared to the same period in the prior year primarily due to continued growth in sales of Rubraca, which is approved for sale in the United States and EU markets. We completed our launch of Rubraca as maintenance therapy in Germany and the UK in March 2019. Product revenue is recorded net of variable considerations comprised of rebates, chargebacks and other discounts. Product revenue for the six months ended June 30, 2019 was $64.6 million in the United States and $1.5 million outside of the United States. Variable considerations represented approximately 14.1% and 10.2% of the transaction price

Table of Contents

recognized in the six months ended June 30, 2019 and 2018, respectively. This increase is spread amongst several variable considerations; in addition, our launch of Rubraca in Germany and the UK in March 2019 contributed to the increase. Amounts are summarized as follows:


	Six months ended				Six months ended
	June 30, 2019				June 30, 2018
	$		% of Gross Sales		$		% of Gross Sales
	(in thousands)				(in thousands)

Transaction price	$	76,983		100.0%	$	47,091		100.0%
Sales deductions:
Government rebates and chargebacks		6,902		9.0%		2,963		6.3%
Discounts and fees		3,985		5.2%		1,849		3.9%
Total sales deductions		10,887		14.1%		4,812		10.2%
Product revenue	$	66,096		85.9%	$	42,279		89.8%

Cost of Sales – Product. Product cost of sales for the six months ended June 30, 2019 increased compared to the same period in the prior year primarily due to the increase in product revenue. Product cost of sales primarily relate to manufacturing, freight and royalties costs associated with Rubraca sales in the period.

Cost of Sales – Intangible Asset Amortization. In the six months ended June 30, 2019 and 2018, we recognized cost of sales of $2.3 million and $1.1 million, respectively, associated with the amortization of capitalized milestone payments related to the approvals of Rubraca by the FDA and the European Commission.

Research and Development Expenses. Research and development expenses increased during the six months ended June 30, 2019 compared to the same period in the prior year primarily due to higher research and development costs for rucaparib. Clinical trial costs for rucaparib were higher compared to the same period a year ago due to increased enrollment in our TRITON3 study for prostate cancer. We have increased costs related to our ATLAS study for bladder cancer and our ATHENA combination study with Bristol-Myers Squibb Company’s immunotherapy OPDIVO for ovarian cancer. Since our ATLAS study for bladder cancer was discontinued in April 2019, costs for this study should gradually decrease during the remainder of 2019. In addition, personnel costs increased during the six months ended June 30, 2019 due to higher headcount to support increased rucaparib clinical trial activities.

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased during the six months ended June 30, 2019 compared to the same period in the prior year primarily due to increased commercialization activities for Rubraca and the increase of costs associated with building out the European infrastructure with the commercialization that occurred on March 1, 2019. This includes an increase of $5.0 million in personnel costs and $5.8 million in marketing costs.

Interest Expense. Interest expense increased during the six months ended June 31, 2019 compared to the same period in the prior year primarily due to the issuance of the 2025 Notes on April 19, 2018.

Legal Settlement Loss. During the first quarter of 2018, we recorded a one-time charge of $8.0 million related to an agreement to resolve a potential litigation claim against us and our officers. We also we recorded a one-time charge of $20.0 million related to an agreement reached with the SEC to resolve its investigation. During the second quarter of 2019, we recorded a one-time charge of $25.0 million to settle the Antipodean Complaint. See Note 15, Commitments and Contingencies for further information regarding this complaint and other legal proceedings.

Other Income. Other income increased during the six months ended June 30, 2018 compared to the same period in the prior year due to interest income earned on our available-for-sale securities.

Liquidity and Capital Resources

To date, we have funded our operations through the public offering of our common stock and convertible debt securities and the private placement of convertible debt securities and preferred stock. At June 30, 2019, we had cash, cash equivalents and available-for-sale securities totaling $315.9 million.

Table of Contents

The following table sets forth the primary sources and uses of cash for the six months ended June 30, 2019 and 2018 (in thousands):


	Six months ended June 30,
	2019		2018

Net cash used in operating activities	$	(196,488)	$	(210,844)
Net cash provided by (used in) investing activities		73,832		(172,208)
Net cash provided by financing activities		9,344		387,382
Effect of exchange rate changes on cash and cash equivalents		43		(207)
Net (decrease) increase in cash and cash equivalents	$	(113,269)	$	4,123

Operating Activities

Net cash used in operating activities resulted primarily from our net losses adjusted for non-cash items and changes in components of working capital. Net cash used in operating activities was lower during the six months ended June 30, 2019 compared to the same period in the prior year primarily due to higher amounts paid for inventory during the six months ended June 30, 2018, partially offset by a higher net loss as adjusted for non-cash items.

Investing Activities

Net cash provided by investing activities for the six months ended June 30, 2019 included sales of available-for-sale securities of $296.8 million partially offset by purchases of available-for-sale securities of $205.8 million and milestone payments of $15.8 million. Net cash used in investing activities in the same period in the prior year included purchases of available-for-sale securities of $125.0 million and milestone payments of $55.0 million partially offset by cash from sales of available-for-sale securities of $10.0 million.

Financing Activities

Net cash provided by financing activities for the six months ended June 31, 2019 included $6.9 million proceeds from borrowings under our financing agreement and $2.5 million received from employee stock option exercises and issuance of stock under the employee stock purchase plan.

Net cash provided by financing activities for the six months ended June 30, 2018 included proceeds of $93.8 million from the sale of common stock, proceeds of $291.0 million from the issuance of convertible senior notes and $2.6 million received from employee stock option exercises and issuance of stock under the employee stock purchase plan.

Operating Capital Requirements

In the United States, Rubraca is approved by the FDA for two indications for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. In the EU, Rubraca is approved by the EMA for two indications for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. We expect to incur significant losses for the foreseeable future, as we commercialize Rubraca and expand our selling, general and administrative functions to support the growth in our commercial organization.

As of June 30, 2019, we had cash, cash equivalents and available-for-sale securities totaling $315.9 million and total current liabilities of $106.1 million. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months. On May 1, 2019, we entered into a financing agreement in aggregate amount up to $175 million whereby we expect to borrow amounts required to reimburse our actual expenses incurred during each fiscal quarter, as such expenses are incurred, related to our ATHENA trial. We have agreed to repay the aggregate borrowed amount plus a return from revenues generated from sales of Rubraca on a quarterly basis, which is anticipated to begin in 2022. See Note 10, Long-term Debt, for additional information.

Table of Contents

●

the number and characteristics of the product candidates, companion diagnostics and indications we pursue;

●

the achievement of various development, regulatory and commercial milestones resulting in required payments to partners pursuant to the terms of our license agreements;

●

the scope, progress, results and costs of researching and developing our product candidates and related companion diagnostics and conducting clinical and non-clinical trials;

●

the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates and companion diagnostics;

●

the cost of commercialization activities, including marketing and distribution costs;

●

the cost of manufacturing any of our product candidates we successfully commercialize;

●

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and outcome of such litigation; and

●

the timing, receipt and amount of sales, if any, of our product candidates.

Contractual Obligations and Commitments

For a discussion of our contractual obligations, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2018 Annual Report on Form 10-K. For further information regarding our contractual obligations and commitments, see Note 15, Commitments and Contingencies to our unaudited consolidated financial statements included elsewhere in this report.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk related to changes in interest rates. As of June 30, 2019, we had cash, cash equivalents and available-for-sale securities of $315.9 million, consisting of bank demand deposits, money market funds and U.S. treasury securities. The primary objectives of our investment policy are to preserve principal and maintain proper liquidity to meet operating needs. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Our available-for-sale securities are subject to interest rate risk and will decline in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our portfolio.

We contract with contract research organizations, investigative sites and contract manufacturers globally where payments are made in currencies other than the U.S. dollar. In addition, on October 3, 2016, we entered into a Manufacturing and Services Agreement with a Swiss company for the production and supply of the active ingredient for Rubraca. Under the terms of this agreement, payments for the supply of the active ingredient in Rubraca as well as scheduled capital program fee payment toward capital equipment and other costs associated with the construction of a dedicated production train will be made in Swiss francs. Once the production train became operational in October 2018, we became obligated to pay a fixed facility fee each quarter for the duration of the agreement, which expires on December 31, 2025.

As of June 30, 2019, $101.3 million of purchase commitments exist under the Manufacturing and Services Agreement, which includes the fixed facility fee noted above, and we are required to remit amounts due in Swiss francs. Due to other variables that may exist, it is difficult to quantify the impact of a particular change in exchange rates. However, we estimate that if the value of the US dollar was to strengthen by 10% compared to the value of Swiss franc as of June 30, 2019, it would decrease the total US dollar purchase commitment under the Manufacturing and Services Agreement by $13.2 million. Similarly, a 10% weakening of the US dollar compared to the Swiss franc would increase the total US dollar purchase commitment by $6.3 million.

While we periodically hold foreign currencies, primarily Euro, Swiss Franc and Pound Sterling, we do not use other financial instruments to hedge our foreign exchange risk. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. As of June 30, 2019 and December 31, 2018, approximately 1% and 6%, respectively, of our total liabilities were denominated in currencies other than the functional currency.

Table of Contents

ITEM 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (“Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Finance Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. With the participation of our Chief Executive Officer and Chief Finance Officer, management performed an evaluation as of June 30, 2019 of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and Chief Finance Officer concluded that, as of June 30, 2019, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1.LEGAL PROCEEDINGS

Rociletinib-Related Litigation

On November 10, 2016, Antipodean Domestic Partners (“Antipodean”) filed a complaint (the “Antipodean Complaint”) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleged that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the offering materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserted Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint sought compensatory, recessionary, and punitive damages. On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint.

On June 14, 2019, Clovis and Antipodean entered into an agreement (the “Settlement Agreement”) to settle the lawsuit. Pursuant to the Settlement Agreement, Clovis agreed to pay Antipodean $4.0 million in cash and issue 1,482,058 shares of common stock of the Company (the “Settlement Shares”) and Antipodean agreed to dismiss the lawsuit and release Clovis, its officers and directors and underwriters from any potential liability related to the allegations asserted in the Amended Complaint. The settlement contains no admission of wrongdoing.

The cash portion of the settlement was paid on June 18, 2019. At June 30, 2019, the liability for the issuance of the shares was recorded to accrued liability for legal settlement on the Consolidated Balance Sheets in the amount of $21.0 million. Clovis issued the Settlement Shares on July 1, 2019, whereby the issuance of the shares was recorded in common stock and additional paid-in capital and the accrued liability for legal settlement was cleared.

As the Settlement Agreement is in response to the alleged violation of securities laws by certain of our officers, we have determined that the resulting loss does not relate to activities that are in the normal course of our operations and therefore, should not be recognized in operating losses for the period. Accordingly, we have recognized the entire expense associated to the Settlement Agreement in legal settlement loss within the other income (expense), net of insurance receivable on the Consolidated Statements of Operations and Comprehensive Loss.

In March 2017, two putative shareholders of the Company, Macalinao and McKenry (the “Derivative Plaintiffs”), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”).

Table of Contents

While the motion to dismiss remained pending, on November 19, 2018, Plaintiffs filed a motion for leave to file a supplemental consolidated complaint, and on November 20, 2018, the Court granted that motion. On November 27, 2018, Plaintiffs filed their supplemental complaint (the “Supplemental Derivative Complaint”), which adds allegations concerning the Company’s, Mr. Mahaffy’s and Mr. Mast’s settlements with the United States Securities and Exchange Commission. Pursuant to a briefing schedule entered by the Court, the defendants filed a supplemental motion to dismiss the Supplemental Derivative Complaint on February 6, 2019; plaintiffs filed an opposition brief on February 22, 2019; and the defendants filed a reply brief on March 5, 2019. The Court held oral arguments on the defendants’ motions to dismiss on June 19, 2019. At the oral arguments, the Court ordered the parties to submit supplemental letter briefs on the motion to dismiss; plaintiffs filed their letter brief on June 25, 2019 and the defendants filed theirs on July 1, 2019.

The Company intends to vigorously defend against the allegations in the Supplemental Derivative Complaint, but there can be no assurance that the defense will be successful.

The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful.

European Patent Opposition

Two oppositions were filed in the granted European counterpart of the rucaparib camsylate salt/polymorph patent on June 20, 2017. The European Patent Office’s Opposition Division held an oral hearing on December 4, 2018, during which it upheld claims, narrowed from the originally granted patent, to certain crystalline forms of rucaparib camsylate, including, but not limited to, rucaparib S-camsylate Form A, the crystalline form in Rubraca. On February 4, 2019, the Opposition Division issued a written decision confirming its decision at the oral hearing. In June 2019, Clovis and one opponent, Hexal, filed briefs appealing the written decision of the European Opposition Division and responses to the appeal briefs are due by November 4, 2019.

ITEM 1A.

RISK FACTORS

Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the risk factors described under the heading “Risk Factors” in Part I, Item 1A of our most recent Annual Report on Form 10-K, ~~as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018,~~ in addition to other information contained in or incorporated by reference into this Quarterly Report on Form 10-Q and our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.

There ~~have~~were no material changes to the risk factors included in our previously filed Annual Report on Form 10-K for the year ended December 31, ~~2017~~2018, other than as ~~supplemented by our Quarterly Report on Form 10-Q for~~highlighted below in connection with entering into the ~~quarter ended March 31, 2018.~~ATHENA

Table of Contents

clinical trial financing agreement. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial also may negatively impact our business.

Our ATHENA clinical trial financing agreement contains a number of covenants and other provisions, which, if violated, could result in the immediate acceleration of our outstanding indebtedness.

~~ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS~~

Pursuant to our ATHENA clinical trial financing agreement, we are required to repay amounts we borrow from the lenders, capped at specific quarterly amounts, based upon the revenues generated from the sales of Rubraca and other amounts we receive in connection with any out-licensing arrangement or settlement we may enter into with respect to Rubraca. If the total payments made on or prior to December 30, 2025 are less than the total amount borrowed prior to such time, we also would be required to make an additional lump-sum payment to the lenders equal to the amount of that shortfall on that date. Following that date, quarterly payments continue until the lenders have received payments equal to twice the amount borrowed under the financing agreement.

Pursuant to the financing agreement, we have agreed to certain limitations on our operations, including limitations on dividends, stock repurchases and repayments of certain indebtedness, and to certain covenants, including with respect to the conduct of the ATHENA trial. Our obligations under the financing agreement are secured by first priority security interests in all of our assets related to Rubraca, including intellectual property rights.

If an event of default (including a breach or default under, or termination of, any of our material in-license agreements and defaults under our other material indebtedness) occurs under the financing agreement, the lenders have the right to demand immediate repayment of our obligations, which may be as high as the greater of (x) twice the amount borrowed thereunder and (y) the amount borrowed thereunder plus either $35 million (if the payment is made in 2019) or $50 million (if the payment is made after 2019).

In addition, if we do not pay our obligations under the financing agreement when due, including at maturity or upon the occurrence of a liquidity event, which includes a change of control of us or upon demand following the occurrence of an event of default, the lenders would have the right to foreclose on the assets we have pledged as collateral and sell those assets, with the proceeds of the sale being applied to repay the indebtedness.

There can be no assurance that we will not breach the covenants or other terms of, or that an event of default will not occur under, the financing agreement and, if a breach or event of default occurs, there can be no assurance that we will be able to obtain necessary waivers or amendments from the lenders or refinance the related indebtedness on terms we find acceptable, or at all. A default under the financing agreement may also trigger defaults under the indentures governing our senior convertible notes.

As a result, any failure to pay our obligations when due, any breach or default of our covenants or other obligations under the financing agreement, or any other event that allows any lender to demand immediate repayment of borrowings, could have a material adverse effect on our business, results of operations, financial condition and prospects. Furthermore, the financing agreement may make us less attractive to potential acquirers; and in the event of a change of control of us, the required discharge of the financing agreement out of our available cash or acquisition proceeds would reduce proceeds available to our stockholders.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

~~ITEM 3.DEFAULTS UPON SENIOR SECURITIES~~
ITEM 3.
DEFAULTS UPON SENIOR SECURITIES

None.

~~Table of Contents~~

~~ITEM 4.MINE SAFETY DISCLOSURES~~
ITEM 4.
MINE SAFETY DISCLOSURES

Not Applicable.

~~ITEM 5.OTHER INFORMATION~~
ITEM 5.
OTHER INFORMATION

None.

Table of Contents

~~10.30+~~10.29+(9)	Indemnification Agreement, dated as of February 17, 2016, ~~by and~~ between Clovis Oncology, Inc. and Daniel W. Muehl.

~~Table of Contents~~

~~10.31+~~10.30+(15)	Employment Agreement, dated as of July 6, 2017, by and between Clovis Oncology, Inc. and Daniel W. Muehl.

~~10.32+~~10.31+(10)	Salary Waiver Letter, dated as of May 9, 2016, by and between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.3310.32(11)	First Amendment to License Agreement, ~~by and~~ between Clovis Oncology, Inc. and Pfizer Inc., dated as of August 30, 2016.

~~10.34+~~10.33+(13)	Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan RSU Agreement.

10.3510.34(13)	Manufacturing Services Agreement, by and between Clovis Oncology, Inc. and Lonza Ltd, dated as of October 3, 2016.

10.3610.35(14)	Strata Trial Collaboration Agreement, by and between Clovis Oncology, Inc. and Strata Oncology, Inc., dated as of January 30, 2017

~~21.1~~10.36+(18)	Indemnification Agreement, dated as of October 11, 2018, between Clovis Oncology, Inc. and Robert W. Azelby.

10.37+(18)	Indemnification Agreement, dated as of October 11, 2018, between Clovis Oncology, Inc. and Richard A. Fair.

10.38+(19)	Employment Agreement, dated as of July 6, 2017, by and between Clovis Oncology, Inc. and Paul Gross.

10.39+(19)	Indemnification Agreement, dated as of September 9, 2016, by and between Clovis Oncology, Inc. and Paul Gross.

10.40(20)	Financing Agreement, dated as of May 1, 2019 among Clovis Oncology, Inc. (the “Company”), certain subsidiaries of the Company named therein, as Guarantors, the Lenders from time to time party thereto, and the Administrative Agent party thereto.
10.41(20)	Pledge and Security Agreement, dated as of May 1, 2019 among each of the Grantors party thereto and the Administrative Agent party thereto.

21.1(17)	List of Subsidiaries of Clovis Oncology, Inc.

31.1	Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2	Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1	Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Table of Contents

101

The following materials from Clovis Oncology, Inc.’s Quarterly Report on Form 10-Q for the period ended June 30, ~~2018,~~2019, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) the Consolidated Statements of Operations and Comprehensive Loss, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Stockholders’ Equity (Deficit), (iv) the Consolidated Statements of Cash Flows and ~~(iv)~~(v) Notes to Unaudited Consolidated Financial Statements.

~~(1)~~

(1)	Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on June 23, 2011.

(2)

~~(2)~~

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on June 14, 2013.

(3)

~~(3)~~

Filed as an exhibit with Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on August 31, 2011.

(4)

~~(4)~~

Filed as an exhibit with Amendment No. 3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on October 31, 2011.

(5)

~~(5)~~

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on March 15, 2012.

(6)

~~(6)~~

Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-180293) on March 23, 2012.

(7)

~~(7)~~

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on November 19, 2013.

(8)

~~(8)~~

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on September 9, 2014.

(9)

~~(9)~~

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on April 1, 2016.

(10)

~~(10)~~

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on May 9, 2016.

(11)

~~(11)~~

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on November 4, 2016.

(12)

~~(12)~~

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 29, 2016.

(13)

~~(13)~~

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 23, 2017.

(14)

~~(14)~~

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on May 4, 2017.

(15)

~~(15)~~

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on July 7, 2017.

~~Table of Contents~~

(16)

~~(16)~~

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on April 19, 2018.

(17)	Filed as an exhibit with the Registrant’s Current Report on Form 10-Q on August 2, 2018.

(18)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on October 12, 2018.

(19)	Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 28, 2019.

(20)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on May 2, 2019.

(21)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on June 6, 2019.

+ Indicates management contract or compensatory plan.

* Confidential treatment has been granted with respect to portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission.

4446

SIGNATURES

~~SIGNATURES~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: August 2, ~~2018~~2019	CLOVIS ONCOLOGY, INC.

	By:	/s/ PATRICK J. MAHAFFY
		Patrick J. Mahaffy
		President and Chief Executive Officer; Director

	By:	/s/ DANIEL W. MUEHL
		Daniel W. Muehl
		~~Senior~~Executive Vice President ofand Chief Finance ~~and Principal Financial and Accounting~~ Officer



PART I. Financial Information				3

~~PART I. Financial Information~~ITEM 1.	3
		Financial Statements (unaudited)	3
~~ITEM 1.~~		~~Financial Statements (unaudited)~~	3

		Consolidated Statements of Operations and Comprehensive Loss — for the three and six months ended June 30, ~~2018~~2019 and June 30, ~~2017~~2018	3


		Consolidated Balance Sheets — as of June 30, ~~2018~~2019 and December 31, ~~2017~~2018	4


		Consolidated Statements of Cash Flows — for the six months ended June 30, ~~2018~~2019 and ~~2017~~2018	5
			7

		Notes to Unaudited Consolidated Financial Statements	6 8

ITEM 2.		Management’s Discussion and Analysis of Financial Condition and Results of Operations	24 26

ITEM 3.		Quantitative and Qualitative Disclosures About Market Risk	36 38

ITEM 4.		Controls and Procedures	37 39

PART II. Other Information			38 40

ITEM 1.		Legal Proceedings	38 40

ITEM 1A.		Risk Factors	40 41

ITEM 2.		Unregistered Sales of Equity Securities and Use of Proceeds	40 42

ITEM 3.		Defaults Upon Senior Securities	40 42

ITEM 4.		Mine Safety Disclosures	41 42

ITEM 5.		Other Information	41 42

ITEM 6.		Exhibits	41 43

SIGNATURES			45 47


	Balance at		Adjustments due to		Balance at
	December 31, 2017		Adoption of ASC 606		January 1, 2018
ASSETS
Accounts receivable, net	$	6,181	$	3,336	$	9,517
Inventories	$	27,508		(62)	$	27,446
Total assets	$	735,230	$	3,274	$	738,504

LIABILITIES AND STOCKHOLDERS' EQUITY
Other accrued expenses	$	25,883	$	918	$	26,801
Accumulated deficit	$	(1,477,440)		2,356	$	(1,475,084)
Total liabilities and stockholders' equity	$	735,230	$	3,274	$	738,504


	Three months ended June 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
Product revenue	$	23,757	$	20,372	$	3,385
Cost of sales - product	$	4,490	$	3,998	$	492
Selling, general and administrative	$	44,864	$	44,679	$	185
Net loss	$	(101,190)	$	(103,898)	$	(2,708)

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(1.94)	$	(1.99)	$	(0.05)


	Six months ended June 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
Product revenue	$	42,279	$	38,328	$	3,951
Cost of sales - product	$	8,495	$	7,539	$	956
Selling, general and administrative	$	84,138	$	83,913	$	225
Net loss	$	(178,885)	$	(181,654)	$	(2,769)

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(3.48)	$	(3.53)	$	(0.05)


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	213,957	$	—	$	(36)	$	213,921


Balance at December 31, 2017	$	65,217
Change in foreign currency gains and losses		(1,742)
Balance at June 30, 2018	$	63,475


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value
	Options	Price		Term (Years)	(Thousands)
Outstanding at December 31, 2017	5,789,735	$	46.77
Granted	475,768		56.47
Exercised	(47,091)		25.82
Forfeited	(114,991)		62.86
Outstanding at June 30, 2018	6,103,421	$	47.39	6.8	$	68,594
Vested and expected to vest at June 30, 2018	5,864,188	$	47.21	6.7	$	67,088
Vested and exercisable at June 30, 2018	4,129,536	$	45.35	5.9	$	54,282


					Change
	Three months ended June 30,				Favorable/(Unfavorable)
	2018		2017		$		%

Product revenue	$	23,757	$	14,620	$	9,137		62	%
Operating expenses:
Cost of sales - product		4,490		2,730		(1,760)		(64)	%
Cost of sales - intangible asset amortization		709		372		(337)		(91)	%
Research and development		52,707		33,108		(19,599)		(59)	%
Selling, general and administrative		44,864		36,149		(8,715)		(24)	%
Total expenses		102,770		72,359		(30,411)		(42)	%
Operating loss		(79,013)		(57,739)		(21,274)		(37)	%
Other income (expense):
Interest expense		(3,581)		(2,598)		(983)		(38)	%
Foreign currency (loss) gain		(104)		76		(180)		(237)	%
Legal settlement loss		—		(117,000)		117,000		100	%
SEC settlement costs reserve		(20,000)		—		(20,000)		(100)	%
Other income		1,475		594		881		148	%
Other expense, net		(22,210)		(118,928)		96,718		81	%
Loss before income taxes		(101,223)		(176,667)		75,444		43	%
Income tax benefit		33		1,281		(1,248)		(97)	%
Net loss	$	(101,190)	$	(175,386)	$	74,196		42	%


	Three months ended				Three months ended
	June 30, 2018				June 30, 2017
	$		% of Gross Sales		$		% of Gross Sales
	(in thousands)				(in thousands)

Transaction price	$	26,390		100.0%	$	15,876		100.0%
Variable considerations:
Government rebates and chargebacks		1,583		5.9%		635		4.0%
Discounts and fees		1,050		4.0%		621		3.9%
Total variable considerations		2,633		9.9%		1,256		7.9%
Product revenue	$	23,757		90.1%	$	14,620		92.1%


	Six months ended				Six months ended
	June 30, 2018				June 30, 2017
	$		% of Gross Sales		$		% of Gross Sales
	(in thousands)				(in thousands)

Gross product revenue	$	47,091		100.0%	$	23,778		100.0%
Sales deductions:
Government rebates and chargebacks		2,963		6.3%		1,072		4.5%
Discounts and fees		1,849		3.9%		1,041		4.4%
Total sales deductions		4,812		10.2%		2,113		8.9%
Product revenue, net	$	42,279		89.8%	$	21,665		91.1%

o
Exhibit
~~Exhibit~~Number	Exhibit Description
~~Number~~	~~Exhibit Description~~

3.1(5)	Amended and Restated Certificate of Incorporation of Clovis Oncology, Inc.

~~3.2(5)~~3.2(21)	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Clovis Oncology, Inc.

3.3(5)	Amended and Restated Bylaws of Clovis Oncology, Inc.

4.1(3)	Form of Common Stock Certificate of Clovis Oncology, Inc.

4.2(8)	Indenture dated as of September 9, 2014, by and between Clovis Oncology, Inc. and The Bank of New York Mellon Trust Company, N.A.

4.3(16)	Indenture dated as of April 19, 2018, by and between Clovis Oncology, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee

4.4(16)	First Supplemental Indenture dated as of April 19, 2018, by and between Clovis Oncology, Inc. and The Bank of New York Mellon Trust Company, N.A.

10.1*(4)	~~Amended and Restated Strategic License Agreement, dated as of June 16, 2011, by and between Clovis Oncology, Inc. and Avila Therapeutics, Inc.~~

~~10.2*(4)~~	License Agreement, dated as of June 2, 2011, by and between Clovis Oncology, Inc. and Pfizer Inc.

~~10.3+~~10.2+(1)	Clovis Oncology, Inc. 2009 Equity Incentive Plan.

~~10.4+~~10.3+(4)	Clovis Oncology, Inc. 2011 Stock Incentive Plan.

~~10.5+~~10.4+(1)	Form of Clovis Oncology, Inc. 2009 Equity Incentive Plan Stock Option Agreement.

~~10.6+~~10.5+(4)	Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan Stock Option Agreement.

~~10.7+~~10.6+(3)	Employment Agreement, dated as of August 24, 2011, by and between Clovis Oncology, Inc. and Patrick J. Mahaffy.

~~10.8+~~10.7+(3)	Employment Agreement, dated as of August 24, 2011, by and between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

~~10.9+~~10.8+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Paul Klingenstein.

~~10.10+~~10.9+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and James C. Blair.

~~10.11+~~10.10+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Edward J. McKinley.



~~10.13+~~10.12+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and M. James Barrett.

~~10.14+~~10.13+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Brian G. Atwood.

~~10.15+~~10.14+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

~~10.16+~~10.15+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Erle T. Mast.

~~10.17+~~10.16+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

~~10.18+~~10.17+(1)	Indemnification Agreement, dated as of May ~~12,~~13, 2009, between Clovis Oncology, Inc. and Andrew R. Allen.

~~10.19+~~10.18+(17)	Clovis Oncology, Inc. 2011 Employee Stock Purchase Plan, as amended.

~~10.20+~~10.19+(4)	Clovis Oncology, Inc. 2011 Cash Bonus Plan.

~~10.21+~~10.20+(6)	Indemnification Agreement, dated as of March 22, 2012, between Clovis Oncology, Inc. and Steven L. Hoerter.

~~10.22+~~10.21+(2)	Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Ginger L. Graham.

~~10.23+~~10.22+(2)	Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Keith Flaherty.

~~10.24(7)~~10.23(7)	Stock Purchase Agreement, dated as of November 19, 2013, by and among ~~the Company,~~Clovis Oncology, Inc., EOS (Ethical Oncology Science) S.P.A., the Sellers listed on Exhibit A thereto and Sofinnova Capital V FCPR, acting in its capacity as the Sellers’ Representative.

10.2510.24(7)	Development and Commercialization Agreement, dated as of October 24, 2008, by and between Advenchen Laboratories LLC and Ethical Oncology Science ~~S.p.A.~~S.P.A., as amended by the First Amendment, dated as of April 13, 2010 and the Second Amendment, dated as of July 30, 2012.

~~10.26+~~10.25+(12)	Indemnification Agreement, effective as of August 3, 2015, between Clovis Oncology, Inc. and Lindsey Rolfe.

10.26+(19)	Amended and Restated Employment Agreement, dated as of February 27, 2019, by and between Clovis Oncology, Inc. and Clovis Oncology UK Limited and Lindsey Rolfe.

10.27+(12)	~~Employment Agreement, dated as of February 25, 2016, by and between Clovis Oncology, Inc. and Lindsey Rolfe.~~

~~10.28+(12)~~	Indemnification Agreement, effective as of February 1, 2016, ~~by and~~ between Clovis Oncology, Inc. and Dale Hooks.

~~10.29+~~10.28+(12)	Employment Agreement, effective as of February 1, 2016, by and between Clovis Oncology, Inc. and Dale Hooks.